MDS NEWS HIGHLIGHTS

FROM THE GUEST EDITOR’S DESK

- HIGH-RISK MDS AND AML: ONE OR TWO DISEASES?
  Michael Heuser, MD, Hannover, Germany

PLAN TO ATTEND
OUR UPCOMING SYMPOSIA
15TH INTERNATIONAL SYMPOSIUM ON MYELODYSPLECTIC SYNDROMES
May 8–11, 2019
Copenhagen, Denmark

IN THIS ISSUE

FROM THE GUEST EDITOR’S DESK 2
MEETING HIGHLIGHTS & ANNOUNCEMENTS
ASH 2019: MDS Breakfast Symposium 6
15th International Symposium on MDS 7
RESEARCH
MDS/MPN International Working Group 14
International Working Group for Prognosis in MDS 15
MDS FOUNDATION LEADERSHIP 16
MDS LITERATURE HIGHLIGHTS 17
MDS CENTERS OF EXCELLENCE 21
MDS FOUNDATION MEMBERSHIP 26
PATIENTS AND CAREGIVERS
LIVING WITH MDS FORUMS 29
PATIENT RESOURCES 30
IN THE NEWS 31
AML CORNER 33
MDS AWARENESS WALK 39
OUR PATIENT STORIES 40
OUR CAREGIVER STORIES 47
CONTRIBUTIONS TO THE FOUNDATION
Gifts 52
Memorial Donations 54
Living Endowments 55

www.mds-foundation.org
Comparison of patient characteristics, genetics and prognosis in high-risk MDS and low blast count AML

Ninety six high-risk MDS and 180 low blast count AML patients were compared in a study by Bacher and colleagues.9 Age, patient sex, cytogenetic risk, blood counts and genetics were almost identical between these two groups. Surprisingly, the blast count had no effect on overall survival. Instead, cytogenetic and molecular aberrations were highly prognostic in these patients. An even larger study was published by DiNardo and colleagues in 2016.10163 patients with high-risk MDS and 230 patients with low blast count AML and 1,159 patients with 30% blasts or more were compared for patient characteristics and outcome. Again, patient characteristics and overall survival were almost identical in high-risk MDS and low blast count AML, while patients with high blast count AML had a higher white blood cell count, higher LDH levels, less often a complex karyotype and were more often NPM1 and FLT3-ITD mutated. Survival was worse for patients with high blast count AML, although the median overall survival differed only by 2.5 months. In multivariate analysis for overall survival marrow blasts were not prognostic between high-risk MDS and low blast count AML, while high blast count AML had a trend for shorter overall survival.

Characteristics between 59 high-risk MDS and 160 MRC-AML patients who all underwent allo-HCT are compared next.11 Patient characteristics and overall survival were almost identical in high-risk MDS and low blast count AML, while patients with high blast count AML had a higher white blood cell count, higher LDH levels, less often a complex karyotype and were more often NPM1 and FLT3-ITD mutated. Survival was worse for patients with high blast count AML, although the median overall survival differed only by 2.5 months. In multivariate analysis for overall survival marrow blasts were not prognostic between high-risk MDS and low blast count AML, while high blast count AML had a trend for shorter overall survival.
cytogenetic aberrations and of molecular aberrations was similar between these two patient cohorts except a higher proportion of TET2 mutations in the MRC-AML cohort. Comparing this cohort of MRC-AML patients to 3,427 de novo AML patients from the AMLSG BiO-registry it becomes clear that these disease types have clear cytogenetic and molecular distinctions: monosomy 7 and 7q-, monosomy 5 and 5q- and RUNX1 and ASXL1 mutations were significantly more frequent in MRC-AML, while CBF leukemias, translocation t(15;17), NPM1, DNMT3A, FLT3-ITD, and CEBPα double mutations were significantly more frequent in de novo AML (AMLSG BiO-registry, unpublished).

In summary, marrow blasts are prognostic in MDS, while they are not prognostic when high-risk MDS is compared to low blast count AML. This already suggested that low blast count AML is more related to high-risk MDS than to de novo AML. In addition, high-risk MDS is genetically related to MRC-AML, while high-risk MDS/MRC-AML is genetically very distinct from de novo AML. MDS therefore seems to develop on a different trajectory than de novo AML. We can classify high-risk MDS and MRC-AML as diseases of the MDS spectrum, which is characterized by mutations in the splicing machinery, ASXL1, RUNX1 and complex karyotype (and likely other mutations). On the other hand, we can classify de novo AML as a disease of the AML spectrum, which is characterized by mutations in NPM1, FLT3, DNMT3A, IDH1, IDH2, CEBPα and by the recurrent fusion genes [Figure 1]. If patients are categorized into MDS and AML based on a blast cut-off of 20%, it is inevitable that patients with an AML spectrum disease will be found in the group of patients with 10 to 19% blasts, while patients with an MDS spectrum disease will be found in the patient cohort with 20 to 29% blasts. By estimate, the patient cohort with 10 to 19% blasts includes approximately 10% of de novo AML patients, while the comparisons of high-risk MDS and low blast count AML, described above, suggest that the patients with 20 to 29% blasts are enriched for high-risk MDS, similarly to the former RAEB-T risk group.

**How do patients with high-risk MDS, low blast count AML and high-blast count AML respond to established and novel treatments?**

Patients with high-risk MDS (in this case 10 to 30% blasts) and patients in the subgroup with 20 to 30% blasts had very similar outcomes when they were treated with azacitidine: Seventeen and 18% of the patients achieved complete remission, respectively, and median overall survival was 24.5 months in both groups. Azacitidine induced a similar CR rate (19.5%) in patients with high blast count AML, while the median overall survival was only 10.4 months. Clearly, this cross study comparison has to be interpreted with caution and the high blast count AML cohort was clearly older than the high-risk MDS cohort.

Intensive chemotherapy was given to a relatively small cohort of patients in these studies and resulted in similar median survival for high-risk MDS (15.7 months), low blast count AML (14.2 months) and high blast count AML (12.2 months). The newly approved drugs in AML have not been thoroughly evaluated in MDS patients. Therefore, their efficacy is compared between MRC-AML and de novo AML patients. In this regard, CPX-351 is beneficial in MRC-AML, as is venetoclax combined with a hypomethylating agent and enasidenib as monotherapy, which has shown preliminary efficacy in IDH2 mutated MDS patients at a similar rate as in AML patients. However, the FLT3 inhibitors midostaurin and sorafenib did not synergize with azacitidine in MDS and secondary AML patients. Similarly, gemtuzumab-ozogamicin combined with cytarabine and idarubicin did not improve the outcome in high-risk MDS and secondary AML patients.

If we now compare again high-risk MDS patients with de novo AML patients, we recognize that these cohorts are different regarding patient characteristics, genetic characteristics, prognosis with azacitidine treatment and in the response to an FLT3 inhibitor combined with a hypo-
methylating agent. In contrast, high-risk MDS and low blast count AML share many features regarding patient characteristics and genetic characteristics including prognosis under azacitidine treatment. Thus, high-risk MDS, low blast count AML and MRC-AML appear to be a common entity sharing genetic features and responsiveness to treatment. In contrast, high-risk MDS with 10 to 19% blasts does not appear to be an early stage of de novo AML.

We have progressed from a time where blast count was a major diagnostic tool to distinguish MDS from AML. We should now incorporate cytogenetic and molecular information in addition to patient history and morphology to distinguish an MDS spectrum disease (high-risk MDS and MRC-AML) from de novo AML. Thus, a genetic profile of MDS related cytogenetic aberrations and mutations in splicing factor genes, ASXL1 and RUNX1 may define a MDS spectrum disease independent of blast count, and a genetic profile of NPM1, FLT3, DNMT3A, IDH1, IDH2, CEBPa, and the common AML fusion genes may define an AML spectrum disease independent of blast count. This proposal certainly needs to be refined and evaluated in large data sets, but could result in a more efficient drug development process. Currently, MRC-AML is again and again shown as a poor risk marker in clinical trials and confounds the efficacy of novel drug treatments that are less efficacious in MRC-AML than in de novo AML. A genetic separation of MDS and AML spectrum diseases may thus improve drug development by tailoring drugs to the right patients. That this approach can improve the outcome especially for MRC-AML patients has been shown by the approval of CPX-351, which was specifically developed in MRC-AML and tAML. Currently, CPX-351 and venetoclax appear as promising drugs besides the established hypomethylating agents in MDS spectrum diseases, while 7+3 based chemotherapy, midostaurin, gemtuzumab-ozogamicin, ivosidenib, enasidenib and venetoclax are available as effective treatments in AML spectrum diseases (Figure 2). In conclusion, high-risk MDS and de novo AML should be treated as different diseases, while it is acknowledged that the therapeutic possibilities especially for the MDS spectrum diseases remain far behind our expectations.

References


MEETING HIGHLIGHTS AND ANNOUNCEMENTS

61ST ASH ANNUAL MEETING & EXPOSITION • DECEMBER 7-10, 2019 • ORANGE COUNTY CONVENTION CENTER ORLANDO, FL

BREAKFAST SYMPOSIUM • DECEMBER 6, 2019

SAVE THE DATE!

PRECISION HEMATOLOGY IN MYELODYSPLASTIC SYNDROMES
ORLANDO, FLORIDA

CONTINUING OUR MISSION OF INTERNATIONAL COLLABORATION IN THE FIELD OF MDS

On behalf of the MDS Foundation and our Board of Directors, THANK YOU for joining our Breakfast Satellite Symposium!

Thank you to all the doctors who presented at and attended our annual American Society of Hematology educational symposium! We reached approximately 350 physicians, researchers and nurses!

THE PRESENTATIONS ARE NOW AVAILABLE ON OUR WEBSITE AT
Welcome to

MDS 2019

On behalf of the Scientific and Local Organizing Committees and the MDS Foundation, it is our pleasure to invite you to the 15th International Symposium on Myelodysplastic Syndromes taking place at the Tivoli Hotel & Congress Center in Copenhagen, Denmark from May 8-11, 2019. As in previous years, the Symposium will cover the most recent discoveries in MDS basic and translational research as well as all relevant clinical aspects of MDS diagnosis, prognosis, and management. The main lectures will be delivered by recognized international leaders in the field, and we look forward to including high-level research presentations, selected from the abstracts submitted by colleagues.

Furthermore, we are very happy to offer you the opportunity to visit wonderful Copenhagen in the spring – and it does not get better than that!

Copenhagen is the lively capital of Denmark which features some of the happiest people in the world, the world’s oldest monarchy and some of the world’s best chefs. Enjoy everything from historic buildings, modern architecture and beautiful art to Tivoli gardens, harbor swims and alternative lifestyles in Christiania.

Join us for a vivid conference - and experience our special Danish way of life.

We look forward to seeing you all in Copenhagen!

Lars Kjeldsen, Jakob Werner Hansen
and Kirsten Grønbæk
Symposium Chairs
## THE 15TH INTERNATIONAL SYMPOSIUM ON
MYELODYSPLASTIC SYNDROMES
COPENHAGEN, DENMARK | 8-11 MAY 2019

**LEGEND:**
- Plenary Session
- Interactive Session
- Meet the Expert
- Nurses Program
- Networking Event
- Industry Sessions
- Young Investigators Award

### WEDNESDAY, MAY 8, 2019

<table>
<thead>
<tr>
<th>TIME</th>
<th>AUDITORIUM 2</th>
<th>AUDITORIUM 3</th>
<th>MEETING ROOM 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00</td>
<td><strong>Workshop I: Basic Science</strong></td>
<td><strong>Workshop II: Clinical Management</strong></td>
<td><strong>Patient and Caregiver Perspectives</strong></td>
</tr>
<tr>
<td></td>
<td>Welcome: Bo Porse</td>
<td>Welcome: Jakob Werner Hansen</td>
<td><strong>Narrative and Experience From a Patient:</strong></td>
</tr>
<tr>
<td></td>
<td>PDX Mouse Models: Dominique Bonnet,</td>
<td>Epidemiology: Jan Nørgaard, Lene</td>
<td>Clement Harlang</td>
</tr>
<tr>
<td></td>
<td>Christophe Come, Hind Medyouf</td>
<td>Granfeldt, Martin Jädersten</td>
<td><strong>Health-Related Quality of Life in Patients</strong></td>
</tr>
<tr>
<td></td>
<td>Dendritic Cells and Monocytes</td>
<td>ICUS/CCUS - How to Handle: Jakob</td>
<td>with MDS: Helle Egeberg Hother</td>
</tr>
<tr>
<td></td>
<td>in Myelodysplastic Syndromes:</td>
<td>Werner Hansen, Luca Malcovati</td>
<td><strong>Patient Ambassador Support (PAS):</strong></td>
</tr>
<tr>
<td></td>
<td>Sine Reker Hadrup, Arjen van de</td>
<td>Clinical Cases: David Bowen,</td>
<td>Kristina Nørskov</td>
</tr>
<tr>
<td></td>
<td>Loosdrecht, Johanna Olweus</td>
<td>Eva Hellström-Lindberg, Magnus</td>
<td><strong>Family Caregiver Ambassador Support (FAMCARE):</strong></td>
</tr>
<tr>
<td></td>
<td>CRISPR/CAS Technology: Rasmus Bak,</td>
<td>Tobiasson</td>
<td>Mary Jarden</td>
</tr>
<tr>
<td></td>
<td>Kristian Helin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Single Cell Sequencing: Adam Mead</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:05</td>
<td><strong>Bioinformatics and Management of</strong></td>
<td><strong>Clinical Management of Familial</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Big Data: Ellia Papaemmanuli, Kyong</td>
<td>Diseases: Patient History and Cases:</td>
<td><strong>Patient Involvement and Self-Management</strong></td>
</tr>
<tr>
<td></td>
<td>Jae Won</td>
<td>Brigitte Schlegelberger, Mette Klarskov</td>
<td>During and After Treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Andersen</td>
<td><strong>Patient Involvement in Treatment - Home</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Based Treatment: Katrine Fridthjof</td>
</tr>
<tr>
<td>14:15</td>
<td><strong>Closing Remarks</strong></td>
<td><strong>Closing Remarks</strong></td>
<td><strong>Patient Activation Through Counseling and</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Exercise in Patients with Acute Leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(PACE–AL) - A Randomized Controlled Trial:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mary Jarden</td>
</tr>
<tr>
<td>15:15</td>
<td><strong>Break</strong></td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td><strong>Opening Ceremony</strong></td>
<td><strong>Patient Involvement and Self-Management During and After Treatment</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>18:30 Introductory Welcome: Kirsten Grønbæk</strong></td>
<td><strong>Patient Involvement in Treatment - Home Based Treatment: Katrine Fridthjof</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>18:40 Welcome from the MDS Foundation: Stephen Nimer</strong></td>
<td><strong>Patient Activation Through Counseling and Exercise in Patients with Acute Leukemia (PACE–AL) - A Randomized Controlled Trial: Mary Jarden</strong></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td><strong>Welcome Reception (Exhibition Area)</strong></td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td><strong>Welcome Reception (Exhibition Area)</strong></td>
<td><strong>Break</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

**AUDITORIUM 1**

18:30 Introductory Welcome: Kirsten Grønbæk
18:40 Welcome from the MDS Foundation: Stephen Nimer
18:50 TBA: Benjamin Ebert
19:20 Tito Bastianello Young Investigator Awards: Stephen Nimer
19:30 Entertainment

20:00 Welcome Reception (Exhibition Area)
### THURSDAY, MAY 9, 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>AUDITORIUM 1</th>
<th>AUDITORIUM 2</th>
<th>AUDITORIUM 3</th>
<th>MEETING ROOM 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:00-08:00</td>
<td>Industry Supported Session</td>
<td>Meet the Expert I: Sideroblastic Anemia: Eva Hellström-Lindberg</td>
<td>Meet the Expert II: Clinical Experience with Immune Check Point Inhibitors in MDS: Casey O’Connell</td>
<td>Meet the Expert III: Iron Chelation: Norbert Gattermann</td>
</tr>
<tr>
<td>07:30-08:00</td>
<td></td>
<td>Meet the Expert I: Sideroblastic Anemia: Eva Hellström-Lindberg</td>
<td></td>
<td>Meet the Expert II: Clinical Experience with Immune Check Point Inhibitors in MDS: Casey O’Connell</td>
</tr>
<tr>
<td></td>
<td>MDS Biology</td>
<td>Chair: Bo Porse and Liran Shlush</td>
<td></td>
<td>Meet the Expert III: Iron Chelation: Norbert Gattermann</td>
</tr>
<tr>
<td>08:00-09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00-11:30</td>
<td>MDS Epigenetic Deregulation</td>
<td>Chair: Kirsten Gronbaek and Jean Pierre Issa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30-13:00</td>
<td>Industry Supported Session</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00-15:00</td>
<td>Personalized Medicine in MDS</td>
<td>Chair: Mario Cazzola and Peter Woll</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00-15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30-17:00</td>
<td>Decision Making in Allogeneic SCT</td>
<td>Chair: Guillermo Sanz and Theo de Witte</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00-19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00-19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Venue</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00-09:15</td>
<td>Auditorium 1</td>
<td>Immune Aberrancies in MDS</td>
<td>Chair: Sine Hadrup and Kulasekararaj</td>
<td></td>
</tr>
<tr>
<td>09:15-09:45</td>
<td>Auditorium 1</td>
<td>Coffee Break, Poster Viewing, and Exhibition Visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45-11:45</td>
<td>Auditorium 1</td>
<td>Therapy I: Modulating the Immune System in MDS Treatment</td>
<td>Chair: Ghulam Mufti and Andreas Due Ørskov</td>
<td></td>
</tr>
<tr>
<td>11:45-13:15</td>
<td>Auditorium 1</td>
<td>Industry Supported Session Not included in main event CME/CPD Credit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15-14:30</td>
<td>Auditorium 1</td>
<td>Therapy II: New Drugs and Combinations</td>
<td>Chair: Luca Malcovati and Ari Giagoundidis</td>
<td></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td>Auditorium 1</td>
<td>Coffee Break, Poster Viewing, and Exhibition Visit</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued on next page
**SATURDAY, MAY 11, 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:30</td>
<td><strong>CMML</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Preclinical Models of CMML (TET2/NRAS) and Sensitivity to MAPK Inhibitor</strong>: Alan Shih</td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentation</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment of CMML Including RAS Mutated</strong>: Raphaël Itzykson</td>
</tr>
<tr>
<td></td>
<td><strong>Oral Presentation</strong></td>
</tr>
<tr>
<td>09:30-10:00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>10:00-10:45</td>
<td><strong>Keynote</strong></td>
</tr>
<tr>
<td></td>
<td><strong>TBA</strong>: David Steensma</td>
</tr>
<tr>
<td>10:45-11:45</td>
<td><strong>Awards and Best Talks</strong></td>
</tr>
<tr>
<td>11:45-12:00</td>
<td><strong>Closing Ceremony</strong></td>
</tr>
</tbody>
</table>
## REGISTRATION

<table>
<thead>
<tr>
<th></th>
<th>REGULAR FEE</th>
<th>LATE/ONSITE FEE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>From March 13 until April 30, 2019</td>
<td>From May 1, 2019</td>
</tr>
<tr>
<td>MDSF member*</td>
<td>€ 700</td>
<td>€ 800</td>
</tr>
<tr>
<td>Non member</td>
<td>€ 800</td>
<td>€ 900</td>
</tr>
<tr>
<td>Hematologists in training **</td>
<td>€ 600</td>
<td>€ 700</td>
</tr>
<tr>
<td>Nurse**</td>
<td>€ 275</td>
<td>€ 325</td>
</tr>
<tr>
<td>Student**</td>
<td>€ 225</td>
<td>€ 250</td>
</tr>
<tr>
<td>Workshop 1: Basic Science***</td>
<td>€ 30</td>
<td>€ 50</td>
</tr>
<tr>
<td>Workshop 2: Clinical Management***</td>
<td>€ 30</td>
<td>€ 50</td>
</tr>
<tr>
<td>Networking Dinner</td>
<td>€ 100</td>
<td>€ 100</td>
</tr>
</tbody>
</table>

* In order to become a member of the MDS Foundation and benefit from reduced fees, please visit the [MDSF Membership website](#).

** In order to benefit from the special fee, a submission of your status confirmation (approval letter signed by the Head of Department or copy of your status ID) must be uploaded during online registration.

*** The Workshops have limited availability and registration is on a first-come first-serve basis.

### FEES FOR ALL MEETING PARTICIPANTS INCLUDE
- Entrance to all scientific sessions
- Access to the exhibition area
- Invitation to the Opening Ceremony & the Welcome Reception
- Coffee & lunch during breaks, as indicated in the program
- Printed material of the Symposium
- Certificate of attendance

### PAYMENT METHODS

Payment of registration fees (in Euro) can be made as follows:

**By Credit Card:** Visa, MasterCard or American Express

**By Bank Transfer:** (Additional 30 Euro handling fee is required)

Please make drafts payable in Euro only to:
Account Name: MDS 2019 Congress, Copenhagen
Bank Details: Credit Suisse Geneva, 1211 Geneva 70, Switzerland
Account Number: 0251-1500934-92-86
IBAN Number: CH21 0483 5150 0934 9208 6
Bank Code: 4835, Swift No: CRESCHZZ12A

Please ensure that the name of the meeting and of the participant is stated on the bank transfer.

Bank charges are the responsibility of the participant and should be paid at source in addition to the registration fees.

Registration will only be valid upon receipt of the full payment by the registration department according to the deadline indicated. An email confirming registration will only be sent after receipt of the required fees.

Outstanding payments will be collected on-site and charged the on-site rate. A copy of the bank transfer (or other proof of payment) will be required in the event that registration fees were not credited to the meeting account on time.

### REGISTRATION CANCELLATION POLICY

All cancellations must be electronically mailed. Refund of registration fee will be as follows:

Note, in case of cancellation at any stage, the Bank transfer handling fee (30 Euro) will not be refunded - applicable to Bank Transfer payments only.

Cancellations received between March 7 to May 1, 2019 - 50% will be refunded

From May 2, 2019 – no refund will be made

### GROUP REGISTRATION

For group registration (10 participants and more) please contact the registration department at: reg_mds19@kenes.com
ACCOMMODATION

MDS 2019 Symposium participants enjoy exclusive rates on their accommodation in Copenhagen. Choose from a wide selection of quality hotels - close to the venue and city center - catering to all budgets.

Browse hotels and book through our secure system on https://hotel.kenes.com/en/congress/MDS19

PATIENT & FAMILY FORUM

Save the Date for Saturday, May 11, 2019

Location: IDA Mødecenter, Kalvebod Brygge 31-33, Copenhagen

FREE One-Day Conference for MDS Patients & Caregivers LIVING with MDS. Whether you are a newly diagnosed patient, a long-term survivor, or caregiver, this event will have something for you. Learn from experts about treatment therapies and strategies for Patients & Caregivers LIVING with MDS.

På www.lyle.dk under arrangementer
Via email til niels@lyle.dk

NETWORKING EVENT

Join us for an evening of networking and discussions with your international colleagues. Meet old friends and make new connections at the Networking Dinner which will take place at

Axelborg on Friday 10 May at 18:30
Michael R. Savona, MD
Vanderbilt University Medical Center
Nashville, Tennessee

The MDS/MPN IWG was established in 2012 and has established a leadership role in research into the pathobiology and novel treatment for MDS/MPN. Since the publication of the Proposed MDS/MPN Response Criteria in 2015,1 the clinical trial opportunities have dramatically increased, including the first investigator-driven, multi-national MDS/MPN-specific trial led by MDS/MPN IWG members: ABNL MARRO. A novel therapy combination in untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes (ABNL-MARRO) is an international basket study designed to allow new compounds and combinations of therapy to be introduced easily among MDS/MPN IWG clinical sites which see MDS/MPN patients, study the biology and pathophysiology of the diseases, and have multilateral expertise in this area. ABNL MARRO-001 is the first MDS/MPN IWG study and is opening spring 2019 in the US, and then in EU countries shortly after.

With **ABNL MARRO-001**, the MDS/MPN IWG aims to validate the proposed criteria for response in MDS/MPN, test QOL tools in patients with MDS/MPN, develop new biomarkers for response to therapy, and augment efforts of large scale prospective genotyping efforts in MDS/MPN.

**References:**
Mutations predict prognosis independent of the IPSS-R: Overview

The International Prognostic Scoring System (IPSS) and IPSS-R were developed by the International Working Group for Prognosis in MDS (IWG-PM) under the aegis of the MDS Foundation and have become the dominant clinical tools for predicting prognosis in patients with myelodysplastic syndromes (MDS). A prognostic scoring system that integrates gene mutations into the known clinical features would have great additive utility for improved determination of prognosis in patients with MDS and has the potential for widespread clinical use. The ongoing project of the IWG-PM Molecular Committee (IWG-PM-M) has shown, with the IPSSR and other scoring systems, using larger molecularly characterized datasets, that mutations are independent predictors of patients’ overall survival. This finding justifies a prognostic scoring system that will integrate clinical and genetic features.

Prognostic Impact of TP53 mutations

A central aim of the IWG-PM Molecular project is to develop a large database of MDS patients with deep clinical annotation and genetic sequencing data for clinical, biologic and possibly therapeutic purposes. In addition to the analysis of previous samples, sequencing additional MDS cases will be performed to further develop the database.

As a first project for the IWG-PM molecular database, the impact of TP53 mutations in 359 MDS patients from 19 collaborative IWG-PM centers demonstrated that this status divides MDS patients with complex karyotypes into distinct prognostic risk groups, with those carrying the mutation having poorer prognoses. Despite their strong associations with adverse clinical and cytogenetic abnormalities that are already incorporated into existing prognostic scoring systems, TP53 mutations carry significant independent prognostic value for decreased survival for patients with MDS.

Recent Molecular Results

Prospective molecular and clinical data on 4270 MDS patients gathered by members of the IWG-PM-Molecular Committee were combined and preliminary analysis was presented at the MDS Symposium of the MDS Foundation at the ASH 2018 meeting. Members of the Coordinating, Oversight, Cytogenetic and Classification Committees along with sequencing performed at Memorial Sloan Kettering Cancer Center have contributed to this ongoing analysis. At least one driver mutation was present in 95% of the patients (median 4). The large size of the cohort allowed for more precise estimates of survival in the less frequently mutated genes. IPSS-R risk groups could be determined for the patients and were strongly associated with survival. 27 genes were mutated in >1.5% of samples and were included for analysis. Mutations in 12 genes were strongly associated with shorter overall survival in univariate analyses. Adjusting the hazard ratio of death for IPSS-R risk groups identified several mutated genes with independent prognostic significance. Association of WHO morphologic MDS subtypes and mutational composition has been characterized. A clinical/mutation score based on survival and AML transformation risk is being developed and validated. Further plans include identifying genetic predictors of response to hypomethylating agents and sequential mutation analysis of disease progression.

Current Project Status, Plans for Sequencing of New Samples

In addition to the above assessment of previous samples, the project will sequence additional large numbers of MDS cases to further develop our database and mutational evaluations. An automated sample management system was recently implemented that links sample reception to library preparation and sequencing submission. The results of these analyses will serve as the template with which to build an integrated molecular risk model for MDS. Also presented at the meeting was the data aggregation update with integration of the data into cBioPortal. This is a mechanism for use of the data by all members of the group for their analyses for investigator-initiated projects.

References

MDS FOUNDATION LEADERSHIP

BOARD OF DIRECTORS

Pierre Fenaux, MD
Hôpital St Louis, Université Paris 7

Peter L. Greenberg, MD
Stanford University School of Medicine

Sandra E. Kurtin, PhD, ANP-C, AOCN
The University of Arizona Cancer Center

Alan F. List, MD
Moffitt Cancer Center

Luca Malcovati, MD
University of Pavia School of Medicine

Stephen D. Nimer, MD, Chair
Sylvester Comprehensive Cancer Center

MEMBERS EMERITUS

John M. Bennett, MD
Rochester, New York, USA

Charlotte M. Niemeyer, MD
Freiburg, Germany

Franz Schmalzl, MD
Innsbruck, Austria

BOARD OF DIRECTORS

Rafael Bejar, MD, PhD
Moores Cancer Center
at the University of California, San Diego

Rena Buckstein, MD, FRCPC
Sunnybrook Health Sciences Centre

Mario Cazzola, MD, Chair
University of Pavia School of Medicine
Fondazione IRCCS Policlinico San Matteo

Jane Churpek, MD
University of Chicago Medicine

Theo J.M. de Witte, MD, PhD
Radboud University Nijmegen Medical Centre
Nijmegen Centre of Molecular Life Sciences

Erin P. Demakos, RN, CCRC
Icahn School of Medicine at Mount Sinai

Benjamin Ebert, MD, PhD
Dana-Farber Cancer Institute

Silvia M. M. Magalhães, MD, PhD
Federal University of Ceará
Hospital Universitário Walter Cantídio

Moshe Mittelman, MD
Tel-Aviv Soursay Medical Center

Yasushi Miyazaki, MD
Oncology Hospital

MEDICAL AND SCIENTIFIC ADVISORY BOARD

Ghulam J. Mufti, DM, FRCPath, FRCP
King’s College London & King’s College Hospital

Seishi Ogawa, MD, PhD
Kyoto University

Uwe Platzbecker, MD
Universitätsklinikum Carl Gustav Carus

Guillermo Sanz, MD
Hospital Universitari y Politècnico La Fe

Akiko Shimamura, MD, PhD
Dana-Farber Cancer Institute

Lewis R. Silverman, MD
Icahn School of Medicine at Mount Sinai

DEVELOPMENT BOARD

Stuart Goldberg, MD
John Theurer Cancer Center at Hackensack
University Medical Center, MDS Specialist

Jennifer Keam, MD, MPH
MDS Caregiver

Deborah Peirce, Chair
Talent/Leadership and Organizational Development Executive, MDS Caregiver

Julia McGuire, Advisor
Executive Vice President, Campbell & Company
Madeleine’s Mom, MDS Patient

INTERNATIONAL NURSE LEADERSHIP BOARD

Erik Aerts, RN
Zürich, Switzerland

Angelika Bitter
Dresden, Germany

Claudia Boglione, RN
Florence, Italy

Karen Campbell, RN
Edinburgh, Scotland, United Kingdom

Hwang Chung Cheng Jordan
Singapore

Nancy Corbitt BSN, RN, OCN, CRNI
Baltimore, Maryland, United States

Nicole Crisp, RN, BScN, MN, NP-adult
Edmonton, Alberta, Canada

Lucy Cussans, RN
North Terrace, Adelaide, Australia

Erin Demakos, RN, CCRC
New York, New York, United States

Rebecca Dring, RN
Melbourne, Australia

Corien Eeltink, RN, MA ANP
Amsterdam, The Netherlands

Lenn Fechter, RN
Stanford, California, United States

Janet Hayden, RN, BSc(hons), MPH
London, United Kingdom

Amelia Hodson, BSN, RN, Clinician II
Charlottesville, Virginia, United States

Miki Iizuka, RN
Tokyo, Japan

Jacqueline Jagger, BA, RN
Gosford, Australia

Natasha L. Johnson, MS, APRN, AOCNP
Tampa, Florida, United States

Christiane Kahle
Dresden, Germany

Sandra E. Kurtin, PhD, ANP-C, AOCN
Tucson, Arizona, United States

Petra Lindroos Kalqvist, RN
Goteborg, Sweden

Arno Mank, RN, PhD
Amsterdam, The Netherlands

R. Denise McAllister, MS, ARNP, AOCNP
Clearwater, Florida, United States

Cindy Murray, RN, MN, NP-adult
Toronto, Ontario, Canada

Geke Ong, RN
London, United Kingdom

Phyllis Paterson, RN, RSCN, Dip Onc
Cambridge, United Kingdom

Jean A. Ridgeway, DNP, APN, NP-C, AOCN
Chicago, Illinois, United States

Natalie Singer, MSc, RN, BSc(Hons)
Glasgow, Scotland, United Kingdom

Samantha Soggee, RN, MN
Heidelberg, Victoria, Australia

Mary L. Thomas, RN, MS, AOCN
Palo Alto, California, United States

Amber Thomassen, AGPCNP-BC, AOCNP
Miami, Florida, United States

Sara M. Tinsley, PhD, ARNP, AOCN
Tampa, Florida, United States

Catherine Vassili, RN, MN
Victoria, Australia

Lauren Ziskind, MSN, NP-C, FNP-BC, OCN
Chicago, Illinois, United States
HIGHLIGHTS OF LATEST LITERATURE IN MDS
SUNEEL D. MUNDLE, PHD
RHEA MUNDLE

Listed below are citations of some new publications relevant to MDS (pathogenesis, clinical characterization, management, etc.). To access the complete articles log on to www.pubmed.gov.

EPIDEMIOLOGY, DIAGNOSIS AND PROGNOSIS:

A total of 1619 cases were identified in SEER database with tMDS/AML among 700,612 adult cases that had a prior history of primary solid tumor malignancy during 2000–2013. The study found significantly elevated risk of tMDS/AML after chemotherapy for 22 of 23 solid tumor types documented. The majority (78%) died with a median survival of 7 mo. The study also estimated that of the total tMDS/AML cases seen in the next 5 years, approximately 3/4 will be post-chemotherapy.


In a retrospective multicenter analysis, bone marrow erythroid cell percentage (Bmery) was determined in diagnostic bone marrow biopsies of 2453 MDS patients. Three distinct categories showed prognostic impact in terms of survival and leukemic transformation (p<0.001); Bmery ≤10% (poor), 11-25% or >25% (intermediate) and 26-45% (good) with median overall survival of 23, 40 and 48 mo respectively (p<0.001). When added to IPSS-R, Bmery was found to enhance the prognostic impact further for both survival and time to AML.

TREATMENT:

ESAs and Growth Factors

The review included 53 articles on 35 studies. A consistent erythroid improvement was seen in 45-73% in ESA-naïve patients, and with previous ESA exposure, the erythroid response rate was 25-75%. The review concludes that erythroid response is durable and also contributes to overall survival. The safety continues to be manageable.

Hypomethylating Agents:

Inhibition of cytidine deaminase (CDA) in gut and liver is necessary for bioavailability of oral decitabine, which is achieved with coadministration of cedazuridine. This phase 1 study showed that an oral combination of 100mg cedazuridine with 30 or 40 mg decitabine produced mean decitabine AUCs closest to the mean AUC of intravenous standard dose decitabine. The toxicity of combination remained consistent with known intravenous decitabine safety profile.

The study included 56 patients with HR MDS and low blast count AML of which 55 received guadecitabine at 60 mg/m²/day SC x 5 days of 28 day cycle (med 3 cycles). The response rate was approximately 14% (8/56), which included 2 complete responses, median duration of response of 11.5 mo, and overall survival in responders was approximately 18 mo (Med survival in all patients was ~7 mo). No or least identified somatic mutations was the only predictive factor for response (p=0.035). Additionally, as seen in a multivariate analysis, high rate of demethylation in blood in the first cycle was associated with response (p=0.03).


Previously untreated AML patients ≥60 yr that were ineligible for intensive chemotherapy (N=82) were treated with a recommended phase 2 dose of venetoclax 600 mg PO daily x 28 day cycle along with low dose cytarabine (20 mg/m² per day). Common grade ≥3 adverse events included febrile neutropenia (42%), thrombocytopenia (38%), leukopenia (34%), with early (30-day) mortality rate of 6%. The CR/CRi was 54%, duration of response (DOR) was 8.1 mo and overall survival (OS) was 10.1 mo. Those without any prior exposure to hypomethylating agents (approx. 70%), had CR/CRi of 62%, DOR 14.8 mo and OS of 13.5mo.


A phase 2, open label, relapse prevention with azacitidine (RELAZA2) study assessed treatment of MDS or AML patients demonstrating measurable residual disease (MRD) after conventional chemotherapy or allogeneic HSCT, with azacitidine 75 mg/m²/day sc on 1–7 day of 29 day cycle x 24 cycles. The baseline MRD status was assessed by either quantitative PCR for relevant gene mutations or in patients with HSCT, by donor chimerism in flow cytometry sorted CD34+ cells. The MRD was reassessed after six cycles of azacitidine. Of the 198 patients screened 60 (30%) had MRD of whom 53 were eligible for treatment. 31/53(58%) were relapse free and alive at 6 mo (p=0.0001) and relapse free survival at 12 mo was 46%. The most common grade 3/4 toxicity was neutropenia.


A phase 3 randomized study tested a combination of platelet supporting eltrombopag (starting-max dose-200–300 mg/day; in East Asians 100–150 mg/day) with azacitidine (75 mg/m²/day sc on 1–7 day of 28 day cycle) versus placebo + azacitidine (1:1 randomization) in Int-1, Int-2 and High-risk MDS patients with baseline platelets <75×10⁹/L. The study was prematurely stopped on advice by IDMC. When stopped, the study showed 16% and 31% patients in eltrombopag vs placebo groups respectively being platelet transfusion free during cycles 1-4 of azacitidine. Overall response in the two groups were 20% and 35% respectively and the hematologic improvement was similar in the two groups. The prominent adverse events in eltrombopag + azacitidine were fibrile neutropenia and diarrhea. Also compared to placebo+ azacitidine control, the eltrombopag combination worsened the platelet recovery, had lower response rate and showed a trend toward increased AML progression.


PARP1 mRNA levels were measured using quantitative RT PCR in bone marrow samples of 77 MDS patients treated with 5-azacytidine. Patients with higher PARP1 mRNA had better response by IWG criteria (p=0.006) and longer survival (p=0.033). A multivariate analysis validated the significance of this observation.

IMiDs:


The phase III MDS-005 study previously demonstrated benefit of lenalidomide in lower risk non del5(q) MDS patients. In the present analysis, an attempt was made to determine a ratio of clinical benefit measured as a composite end point of transfusion independence/reduction by 4pRBC units, Hb increase of ≥1.5 g/dL or cytogenetic response to risk of hematologic adverse events (B/R: composite end point /AEs). The clinical benefit was seen in approximately 32% patients treated with lenalidomide versus approximately 4% on placebo. The clinical benefit was likely in patients who had ≥1 dose reduction due to toxicity than patients without any dose reductions.

Novel Therapies:

A phase II randomized open label multicenter study evaluated a hedgehog pathway inhibitor glasdegib (100 mg PO QD x 28 day cycle) in combination with low dose ara-C (LDAC; 20 mg SC BID, 10 days in 28 day cycle, n=88) versus LDAC alone (n=44) in newly diagnosed AML or HR-MDS. Median overall survival was 8.8 mo with combination vs. 4.9 mo with LDAC (HR=0.51, p=0.0004) and complete responses were noted in 17% vs 2.3% in the two groups respectively (p<0.05). Among non-hematologic Grade 3/4 adverse events, while pneumonia was seen in both groups (~17% vs 15% respectively), fatigue was seen with the combination (14%).


A case report of concurrent melanoma and AML treated with pembrolizumab showed platelet response and clearance of IDH1 mutations. Additionally, response to pembrolizumab was associated with PD-L1 expression on AML blasts and T cells.

PATHOBIOLOGY:

A transcriptomic analysis of 265 MDS bone marrows and validation with CRISPR/Cas-9 mediated gene editing showed that the SF3B1 intron retaining isoforms were the most frequently observed splicing alteration in SF3B1 mutated samples. Tumor suppressors and genes of mitochondrial iron metabolism or heme biosynthesis appear to be the target genes.


This study by the International Working Group for MDS Molecular Prognostic Committee examined 359 complex karyotype MDS (CK MDS) cases. TP53 mutated patients showed fewer co-mutations, but were enriched for del(5q) (p<0.005), monosomal karyotype (p<0.001) and high complexity with >4 cytogenetic abnormalities (p<0.001). The monosomal karyotype, high complexity and TP53 mutations were individually associated with poorer overall survival. The poor prognosis of CK MDS thus seems to be related to its association with TP53 mutations.


Using RNA-Seq, CD34+ cell transcriptome was evaluated in MDS and two distinct expression profiles differentiated the patients who remained stable versus who transformed into AML within 12 mo. When combined with exomic analysis, distinct gene isoforms emerged within MDS mutational subgroups correlating with characteristic functional impairments.


This study in mice demonstrated cooperation between epigenetic mechanism with proliferation signaling pathway in leukemogenesis. Concomitant mutational loss of ASXL1 and the haploinsufficiency in NF1 (negative regulator of Ras signaling) was shown to cause transcriptional activation of critical pathways for myeloid proliferation.

REVIEWS, PERSPECTIVES & GUIDELINES

The following articles provide significant review of literature and/or innovative perspective on the state-of-the-art in MDS or discuss therapeutic management guidelines and identify need for additional prospective studies.


4. Sallman DA and List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic
Ineffective erythropoiesis in patients with myelodysplastic syndromes (MDS) has long been regarded as arising from apoptosis provoked by inflammatory cytokines. We now recognize that aberrant innate immune activation within the malignant clone directs pro-inflammatory circuits that serve as key pathogenic drivers of the disease. In particular, S100A9-mediated NLRP3 inflammasome activation directs what is recognized as an implementory, lytic form of cell death termed pyroptosis that underlies many of the characteristic features of the disease. This circuit, which results in the release of other danger-associated molecular patterns (DAMPs), expands bone marrow myeloid derived suppressor cells (MDSC), creating a feed-forward process that reinforces inflammasome activation. Somatic gene mutations of a varied functional classes license the NLPR3 inflammasome to generate a common phenotype with excess reactive oxygen species generation, Wnt/ß-catenin-induced proliferation, cation flux-induced cell swelling, caspase-1 activation and gasdermin-D cleavage to generate pyroptotic erythroid precursors and the variant allele frequency or number of somatic mutations. Importantly, knockdown of NLRP3 suppress pyroptosis, ROS generation, and nuclear beta-catenin in MDS primary specimens and are intermediates in inflammasome signaling offer the potential for development of novel classes of anemia modifying agents for MDS.

LITERATURE HIGHLIGHTS


NEW ABSTRACT

Presented at: INTERNATIONAL CONFERENCE ERYTHROPOIESIS CONTROL AND INEFFECTIVE ERYTHROPOIESIS: FROM BENCH TO BEDSIDE.

INFLAMMATION AS A DETERMINANT OF INEFFECTIVE ERYTHROPOIESIS IN MYELODYSPLASTIC SYNDROMES

ALAN F. LIST, MD, Moffitt Cancer Center, Tampa, FL

Ineffective erythropoiesis in patients with myelodysplastic syndromes (MDS) has long been regarded as arising from apoptosis provoked by inflammatory cytokines. We now recognize that aberrant innate immune activation within the malignant clone directs pro-inflammatory circuits that serve as key pathogenic drivers of the disease. In particular, S100A9-mediated NLRP3 inflammasome activation directs what is recognized as an implementory, lytic form of cell death termed pyroptosis that underlies many of the characteristic features of the disease. This circuit, which results in the release of other danger-associated molecular patterns (DAMPs), expands bone marrow myeloid derived suppressor cells (MDSC), creating a feed-forward process that reinforces inflammasome activation. Somatic gene mutations of a varied functional classes license the NLRP3 inflammasome to generate a common phenotype with excess reactive oxygen species generation, Wnt/ß-catenin-induced proliferation, cation flux-induced cell swelling, caspase-1 activation and gasdermin-D cleavage to generate pyroptotic erythroid precursors and the variant allele frequency or number of somatic mutations. Importantly, knockdown of NLRP3 suppress pyroptosis, ROS generation, and nuclear beta-catenin in MDS primary specimens and are intermediates in inflammasome signaling offer the potential for development of novel classes of anemia modifying agents for MDS.
MDS CENTERS OF EXCELLENCE

Our MDS Centers of Excellence are institutions that meet the highest standards for diagnosis, treatment and patient care. These centers help patients seeking first or second opinions and/or additional treatment options from experts in MDS. We currently have 72 Centers in the United States and 112 Centers in countries around the world. Our MDS Centers can be viewed here: https://www.mds-foundation.org/mds-centers-of-excellence

BENEFITS OF MEMBERSHIP:
- MDSF CoEs form the referral base for the patients who contact the Foundation daily.
- MDSF CoEs are proudly recognized on the Foundation website, within our printed newsletters, and through our various social media platforms.
- MDSF CoEs are offered reduced registration rates at our Int’l Symposia and discounted subscription rates to Leukemia Research.
- MDSF CoEs have full access to MDSF educational resources for distribution to your patients.
- In addition, along with your $500 CoE renewal payment, your annual MDSF Professional Membership dues are waived.
- MDSF Professional Members are also listed, by name, on our website and in our printed newsletters.
- The work of your institution can be shared with our patient and professional contacts via our website and/or our social media channels. We can spread the word of your clinical trials, research projects, etc.

Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence?

To be recognized as a Center of Excellence, an institution must have the following:
- An established university (or equivalent) program
- Recognized morphologic expertise in MDS
- Available cytogenetics and/or molecular genetics
- Ongoing research, including Institutional Review Board–approved clinical trials
- Documentation of peer-reviewed publications in the field

Please contact the Foundation for further information and an application form for your center.

The following centers have qualified as MDS Centers of Excellence:

UNITED STATES

ALABAMA
University of Alabama at Birmingham
Birmingham Comprehensive Cancer Center
Birmingham, Alabama
Kimo Bachiaashvili, MD

ARIZONA
Mayo Clinic Hospital
Phoenix, Arizona
Lisa Sproat, MD

The University of Arizona Cancer Center
Tucson, Arizona
Ravi Krishnaswami, MD, FACP

CALIFORNIA
Cedars-Sinai Medical Center
UCLA School of Medicine
Los Angeles, California
H. Phillip Koehler, MD
City of Hope National Medical Center
Duarte, California
Stephen J. Forman, MD

Moore Cancer Center–UC San Diego Health
San Diego, California
Rafael Bejar, MD, PhD
Peter Curtin, MD

Stanford University Medical Center
Stanford, California
Peter L. Greenberg, MD

UCLA Health Hematologic Malignancies and Stem Cell Transplant Program
Los Angeles, California
Gary J. Schiller, MD
University of Southern California
Keck School of Medicine
Los Angeles, California
Casey L. O’Connell, MD

COLORADO
University of Colorado School of Medicine
University of Colorado Cancer Center
Aurora, Colorado
Daniel Aaron Pollyea, MD, MS

CONNECTICUT
Yale Cancer Center/Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut
Steven D. Gore, MD

FLORIDA
Mayo Clinic
Jacksonville, Florida
James M. Foran, MD

Moffitt Cancer Center
Tampa, Florida
Alan F. List, MD

Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine
Miami, Florida
Stephen D. Nimer, MD

University of Florida
Shands Hospital
Gainesville, Florida
Christopher R. Cogle, MD

GEORGIA
Emory Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Amelia Langston, MD

The Blood and Marrow Transplant Program at Northside Hospital
Atlanta, Georgia
Asad Bashey, MD

ILLINOIS
Loyola University Chicago
Cardinal Bernardin Cancer Center
Maywood, Illinois
Scott E. Smith, MD, PhD

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Olga Frankfurt, MD

Rush University Medical Center
Chicago, Illinois
Jamile Shammo, MD

University of Chicago Medical Center
Chicago, Illinois
Richard A. Larson, MD
INDIANA
Indiana University Simon Cancer Center
Indianapolis, Indiana
Larry Cripe, MD/Hamid Sayar, MD, MS

IOWA
The University of Iowa Hospitals and Clinics, Holden Cancer Center
Iowa City, Iowa
Carlos E. Vigil-Gonzales, MD

KANSAS
The University of Kansas Cancer Center
Westwood, Kansas
Barry Skikne, MD

MARYLAND
Johns Hopkins University School of Medicine
Baltimore, Maryland
Amy Elizabeth DeZern, MD
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Maria R. Baer, MD

MASSACHUSETTS
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts
Akiko Shimamura, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts
Richard M. Stone, MD/David P. Steensma, MD
Benjamin Ebert, MD, PhD
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Timothy Graubert, MD
Tufts University School of Medicine
Tufts Medical Center
Boston, Massachusetts
Kellie Sprague, MD

MICHIGAN
Barbara Ann Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Charles A. Schiffer, MD
William Beaumont Hospital Cancer Center
Royal Oak, Michigan
Ishmael Jaiyesimi, DO

MINNESOTA
Mayo Clinic
Rochester, Minnesota
Mark R. Litzow, MD
University of Minnesota Medical Center, Fairview University of Minnesota Medical School
Minneapolis, Minnesota
Erica D. Warfield, MD

MISSOURI
Washington University School of Medicine
Siteman Cancer Center
St. Louis, Missouri
John F. DiPersio, MD, PhD

NEBRASKA
University of Nebraska Medical Center
Omaha, Nebraska
Lori Maness, MD

NEW HAMPSHIRE
Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center
Lebanon, New Hampshire
Kenneth R. Meehan, MD

NEW JERSEY
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Stuart Goldberg, MD
Rutgers Cancer Institute of New Jersey
Rutgers University Hematologic Malignancies and Stem Cell Transplant
New Brunswick, New Jersey
Dale G. Schaaf, MD, PhD

NEW MEXICO
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico
Cecilia Arana Yi, MD

NEW YORK
Albert Einstein Cancer Center/Albert Einstein College of Medicine of Yeshiva University
Bronx, New York
Amit Verma, MD
Columbia University Medical Center
New York, New York
Azra Raza, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Virginia M. Klimk, MD
Northwell Health Cancer Institute at Montefiore Medical Center
Bronx, New York
Steven L. Allen, MD
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Roel Tijssen, MD, PhD
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York
Karen Seiter, MD

Roswell Park Cancer Center
Buffalo, New York
Elizabeth Griffiths, MD/James E. Thompson, MD
University of Rochester Medical Center
Rochester, New York
Jane L. Liedsvold, MD
Weill Medical College of Cornell University
New York Presbyterian Hospital
New York, New York
Gail J. Roboz, MD

NORTH CAROLINA
Duke University Medical Center
Durham, North Carolina
Carlos M. deCastro, MD
Wake Forest University School of Medicine Comprehensive Cancer Center
Winston-Salem, North Carolina
Bayard L. Powell, MD

OHIO
Cleveland Clinic Foundation Taussig Cancer Center
Cleveland, Ohio
Jaroslav Maciejewski, MD, PhD
Mikael Sekeres, MD, MS
Hoxworth Blood Center
George L. Strike Bone Marrow Transplant Program
University of Cincinnati – UC Health
Cincinnati, Ohio
Zartash G. Gol, MD
The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute
Columbus, Ohio
James S. Blachly, MD/Alison R. Walker, MD

PENNSYLVANIA
Allegheny Health Network Cancer Institute
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Salman Fazal, MD
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Philip Panciari, MD
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
Selina Luger, MD
UPMC Cancer Center
Pittsburgh, Pennsylvania
Anastasios Raptis, MD/James M. Rossetti, DO

TENNESSEE
Vanderbilt University Medical Center
Nashville, Tennessee
Sanjay Mohan, MD/Michael R. Savona, MD
<table>
<thead>
<tr>
<th>State</th>
<th>Institution</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEXAS</td>
<td>Texas Oncology – San Antonio</td>
<td>San Antonio, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>Houston, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Texas Southwestern Medical Center</td>
<td>Dallas, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Virginia</td>
<td>Charlottesville, Virginia</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Texas Oncology, Midtown</td>
<td>Austin, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Texas Oncology – San Antonio</td>
<td>San Antonio, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>Houston, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Texas Southwestern Medical Center</td>
<td>Dallas, Texas</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Virginia</td>
<td>Charlottesville, Virginia</td>
<td>United States</td>
</tr>
<tr>
<td>UTAH</td>
<td>University of Utah Huntsman Cancer Institute</td>
<td>Salt Lake City, Utah</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Utah Huntsman Cancer Institute</td>
<td>Salt Lake City, Utah</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Utah Huntsman Cancer Institute</td>
<td>Salt Lake City, Utah</td>
<td>United States</td>
</tr>
<tr>
<td>VIRGINIA</td>
<td>University of Virginia</td>
<td>Charlottesville, Virginia</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Virginia</td>
<td>Charlottesville, Virginia</td>
<td>United States</td>
</tr>
<tr>
<td>WASHINGTON</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>Seattle, Washington</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Seattle Cancer Care Alliance</td>
<td>Seattle, Washington</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Washington</td>
<td>Seattle, Washington</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>George Washington University VA Medical Center</td>
<td>Washington, D.C.</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>George Washington University VA Medical Center</td>
<td>Washington, D.C.</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>George Washington University VA Medical Center</td>
<td>Washington, D.C.</td>
<td>United States</td>
</tr>
<tr>
<td>WASHINGTON, DC</td>
<td>Georgetown University Hospital Lombardi Comprehensive Cancer Center</td>
<td>Washington, D.C.</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Georgetown University Hospital Lombardi Comprehensive Cancer Center</td>
<td>Washington, D.C.</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Georgetown University Hospital Lombardi Comprehensive Cancer Center</td>
<td>Washington, D.C.</td>
<td>United States</td>
</tr>
<tr>
<td>WISCONSIN</td>
<td>American Family Children’s Hospital University of Wisconsin Health</td>
<td>Madison, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Wisconsin Health</td>
<td>Madison, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Medical College of Wisconsin Bone Marrow Transplant Program</td>
<td>Milwaukee, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Medical College of Wisconsin Bone Marrow Transplant Program</td>
<td>Milwaukee, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>Medical College of Wisconsin Bone Marrow Transplant Program</td>
<td>Milwaukee, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Wisconsin Madison Medical School</td>
<td>Madison, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Wisconsin Madison Medical School</td>
<td>Madison, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td></td>
<td>University of Wisconsin Madison Medical School</td>
<td>Madison, Wisconsin</td>
<td>United States</td>
</tr>
<tr>
<td>OUTSIDE THE UNITED STATES</td>
<td>ARAGUANTINA</td>
<td>Sanatorio Sagrado del Corazón</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td></td>
<td>Sanatorio Sagrado del Corazón</td>
<td>Buenos Aires, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td></td>
<td>Sanatorio Sagrado del Corazón</td>
<td>Buenos Aires, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td></td>
<td>Sanatorio Sagrado del Corazón</td>
<td>Buenos Aires, Argentina</td>
<td>Argentina</td>
</tr>
<tr>
<td>ARGENTINA</td>
<td>Muratsan University Hospital Complex of Yerevan State Medical University</td>
<td>Yerevan, Armenia</td>
<td>Armenia</td>
</tr>
<tr>
<td></td>
<td>Muratsan University Hospital Complex of Yerevan State Medical University</td>
<td>Yerevan, Armenia</td>
<td>Armenia</td>
</tr>
<tr>
<td></td>
<td>Muratsan University Hospital Complex of Yerevan State Medical University</td>
<td>Yerevan, Armenia</td>
<td>Armenia</td>
</tr>
<tr>
<td>ARMENIA</td>
<td>Cabirini Haematology &amp; Oncology Centre</td>
<td>Melbourne, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>Cabirini Haematology &amp; Oncology Centre</td>
<td>Melbourne, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>Cabirini Haematology &amp; Oncology Centre</td>
<td>Melbourne, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>AUSTRALIA</td>
<td>Monash Health Monash University</td>
<td>Clayton, Victoria, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>Monash Health Monash University</td>
<td>Clayton, Victoria, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td></td>
<td>Monash Health Monash University</td>
<td>Clayton, Victoria, Australia</td>
<td>Australia</td>
</tr>
<tr>
<td>AUSTRIA</td>
<td>Hanusch Hospital Medical University of Vienna</td>
<td>Vienna, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td>Hanusch Hospital Medical University of Vienna</td>
<td>Vienna, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td></td>
<td>Hanusch Hospital Medical University of Vienna</td>
<td>Vienna, Austria</td>
<td>Austria</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>AZ Sint-Jan AV Brugge, Belgium</td>
<td>Brugge, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td></td>
<td>AZ Sint-Jan AV Brugge, Belgium</td>
<td>Brugge, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td></td>
<td>AZ Sint-Jan AV Brugge, Belgium</td>
<td>Brugge, Belgium</td>
<td>Belgium</td>
</tr>
<tr>
<td>CANADA</td>
<td>Princess Margaret Hospital Toronto, Ontario, Canada</td>
<td>Toronto, Ontario, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td></td>
<td>Sunnybrook Cancer Centre</td>
<td>Toronto, Ontario, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td></td>
<td>Sunnybrook Cancer Centre</td>
<td>Toronto, Ontario, Canada</td>
<td>Canada</td>
</tr>
<tr>
<td>CHINA</td>
<td>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences Guangzhou, China</td>
<td>Guangzhou, China</td>
<td>China</td>
</tr>
<tr>
<td></td>
<td>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences Guangzhou, China</td>
<td>Guangzhou, China</td>
<td>China</td>
</tr>
<tr>
<td></td>
<td>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences Guangzhou, China</td>
<td>Guangzhou, China</td>
<td>China</td>
</tr>
<tr>
<td>CROATIA</td>
<td>Clinical Hospital Merkur Zagreb, Croatia</td>
<td>Zagreb, Croatia</td>
<td>Croatia</td>
</tr>
<tr>
<td></td>
<td>Clinical Hospital Merkur Zagreb, Croatia</td>
<td>Zagreb, Croatia</td>
<td>Croatia</td>
</tr>
<tr>
<td></td>
<td>Clinical Hospital Merkur Zagreb, Croatia</td>
<td>Zagreb, Croatia</td>
<td>Croatia</td>
</tr>
<tr>
<td>CZECH REPUBLIC</td>
<td>Institute of Hematology &amp; Blood Transfusion Prague, Czech Republic</td>
<td>Prague, Czech Republic</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td>Institute of Hematology &amp; Blood Transfusion Prague, Czech Republic</td>
<td>Prague, Czech Republic</td>
<td>Czech Republic</td>
</tr>
<tr>
<td></td>
<td>Institute of Hematology &amp; Blood Transfusion Prague, Czech Republic</td>
<td>Prague, Czech Republic</td>
<td>Czech Republic</td>
</tr>
<tr>
<td>DENMARK</td>
<td>Odense University Hospital The University of Southern Denmark Odense, Denmark</td>
<td>Odense, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td></td>
<td>Odense University Hospital The University of Southern Denmark Odense, Denmark</td>
<td>Odense, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td></td>
<td>Odense University Hospital The University of Southern Denmark Odense, Denmark</td>
<td>Odense, Denmark</td>
<td>Denmark</td>
</tr>
<tr>
<td>ECUADOR</td>
<td>Universidade Federal de São Paulo São Paulo, Brazil</td>
<td>São Paulo, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td></td>
<td>Universidade Federal de São Paulo São Paulo, Brazil</td>
<td>São Paulo, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td></td>
<td>Universidade Federal de São Paulo São Paulo, Brazil</td>
<td>São Paulo, Brazil</td>
<td>Brazil</td>
</tr>
<tr>
<td>EGYPT</td>
<td>University of Utah Huntsman Cancer Institute</td>
<td>Salt Lake City, Utah</td>
<td>United States</td>
</tr>
</tbody>
</table>
MDS FOUNDATION MEMBERSHIP

BENEFITS OF MEMBERSHIP

• You are part of the solution to change MDS outcomes. Your membership fee helps support global physician and patient educational initiatives, and helps to empower patients with courage and hope.

• Updates on the status of our Global Centers of Excellence and their live patient and family forum events that allow for more rapid dissemination of new research and treatment developments.

• Information on the latest clinical trials to potentially share or participate in.

• Access to MDS awareness materials to share with family and friends.

• Opportunities to participate in or host support group events with your friends and community.

• Receive two printed issues of The MDS News, which includes the latest on MDS research as well as inspiring patient and caregiver stories.

YOUR MEMBERSHIP MAKES A DIFFERENCE

$35 Community Membership (includes benefits listed above)

$70 Sharing Hope Membership (includes benefits listed above as well as a membership scholarship for a patient or caregiver in need)

$250 Changing the Future of MDS Membership (includes benefits listed above as well as additional support for the MDS Foundation as we work together to change the future of MDS). Member names are listed on the MDSF website.

“She asked if I would like for her to make an appointment. We had an appointment WITHIN A WEEK and were treated royally. That is some seriously appreciated clout. Now anyone out there experiencing MDS in your family or with friends I tell from experience there is ONLY ONE KIND of doctor you should be seeing: A DOCTOR RECOMMENDED BY THE MDS FOUNDATION”

The Fournier Family
Tim Fournier, MDS Patient, 79 years old, 3 children, 8 grandchildren

“It took a long time to wrap our heads around a disease without a cure when my husband felt just fine — The MDS Foundation gave me the information I so badly needed to be a good caregiver. The MDS Foundation was there when we needed it desperately.”

The Cook Family
Janice Cook, MDS Caregiver, 70 years old, 2 children, 1 grandchild (“Grandpa’s best medicine”)

“When I was diagnosed with MDS in 2008, the MDS Foundation became my primary source of accurate, comprehensive and understandable information about this complex and challenging bone marrow disease.

I donate to the MDS Foundation because it’s an unparalleled resource for patients, caregivers, treatment providers and researchers. Additionally, I donate because of the wonderful, caring professional staff.”

MDS patient, 68 years old

TO BECOME A MEMBER VISIT:
https://www.mds-foundation.org/membership
THINKING OF JOINING THE MDS FOUNDATION AS A PROFESSIONAL MEMBER?

To join the MDS Foundation and help us fulfill our mission of moving closer to a cure for MDS, please visit our website at http://www.mds-foundation.org/professional-annual-membership-application.

CURRENT PROFESSIONAL MEMBERS: Camille Abboud, MD • Aref Al-Kali, MD • Steven Alle, MD • Sergio Amadori, MD • Kimo Bachiashvili, MD • Maria Baer, MD • Stefan Balabanov, MD • Indira Barbosa, BMA • Asad Bashey, MD, PhD • Mariëlle Beckers, MD, PhD • Rafael Bejar, MD, PhD • John M. Bennett, MD • Léa Bernard, MD, FRCP • Emmanuel C. Besa, MD • Ann-Charlotte Björklund • James Blachly, MD • Nicolas Bonadies, MD • Andrew M. Brunner, MD, PhD • Rina Buckstein, MD, FRCP • Gesine Bug, MD • Jaroslav Cermak, MD, PhD • Victor Chang, MD, FACP • Suning Chen, MD, PhD • June-Won Cheong, MD • Christopher Cogle, MD • Robert Collins, Jr., MD, FACP • Seth J. Corey, MD • Larry Crife, MD • Peter T. Curtin, MD • Magdalena Czader, MD, PhD • Christopher Dalley, MD • Matthew De Silva • Theo de Witte, MD, PhD • Carlos de Castro, MD • H. Joachim Deeg, MD • Michel Delforge, MD, PhD • Matteo Della Porta, MD • Mike Dennis, MD • Amy E. DeZern, MD, MHS • Maria Diez-Campelo, MD, PhD • John DiPersio, MD, PhD • Yigal Dror, MD • Erika Eksioglu, PhD, MS • M. Tarek Elghetany, MD • Salmon Fazal, MD • Kalman Filanovsky, MD • Peggy Finston, MD • James Foran, MD, FRCP • Stephen Forman, MD • Olga Frankfurt, MD • Noah Ganser, MD • Alejandro Garcia-Hernandez, MD • Guillermo Garcia-Manero, MD • Ulrich Germing, MD • Stuart Goldberg, MD • Steven Gore, MD • Katharina Gotze, MD, PhD • Marie Pierre Gourin, MD • Timothy Graubert, MD • Peter L. Greenberg, MD • Stephanie A. Gregory, MD • Elizabeth Griffiths, MD, PhD • Sofia Grille, MD, PhD • Kirsten Grønbæk, Professor, MD • Zartash Gul, MD • Emmanuel Gyan, MD, PhD • Detlef Haase, MD, PhD • Torsten Haferlach, MD • Gregory Hale, MD • Robert Hasserjian, MD • Stefan Heinrichs, PhD • Michel Hoessly, MD • Aaron Hoskins, PhD • Gang Huang, PhD • Ishmael Jaiyesimi, MD • Monika Jansson • Brian A. Jonas, MD, PhD • Mark Juckett, MD • Hagop Kantarjian, MD • Jonathan Kell, MD • Melita Kenedy, MD • Michael Keng, MD • Wolfgang Kern, MD, Professor • Sally Killick, MD • Lars Kjeldsen, MD, PhD • Jeffrey Klic, MD • Virginia M. Klimk, MD • Rami Komrokji, MD • Nicolaus Kroger, MD, PhD • Saskia Langemeijer, MD, PhD • Amelia Langston, MD • Richard Larson, MD • Heather Leitch, MD, PhD • Xiao Li, MD • Jane Liesveld, MD • Alan List, MD • Mark Litzow, MD • Selina Luger, MD • Roger Lyons, MD, FACP • Ulrich Mahlknecht, MD, PhD • Inga Mandac Rogulj, MD • Lori Maness, MD • Markus Manz, MD • Claus Marcher, MD, PhD • Akira Matsuda, MD • Philip McCarthy, MD • Stephen Medlin, DO • Kenneth Meehan, MD • Raul R. Mena, MD • Moshe Mittelman, MD • Yasushi Miyazaki, MD • Sanjay Mohan, MD • Joseph Moore, MD • Teresa Morera Blanco, PhD • Lynn Moschinski, MD • Srinivasan Narayanan, MD • Shyamala Navada, MD • Charlotte Niemeyer, MD • Stephen Nimer, MD • Casey O’Connell, MD • Kiroyuki Ogata, MD, PhD, FACP • Philip Pancari, MD • Stefani Parmentier, MD • Jakob Passweg, MD, MS • Michael Pfeilstöcker, MD • Uwe Platzbecker, MD • Daniel Polleya, MD, MS • Bayard Powell, MD • Bruno Quetsel, MD • Markus Radsak, MD, PhD • Fernando Ramos, MD, PhD, MPH • Vishal Ranpura, MD • Klas Raaschou-Jensen, MD • Michael Rauh, MD • Azra Raza, MD • Brandi Reeves, MD • Kevin Rouault-Pierre, PhD • Alicia Rovo, MD • David Sallman, MD • Marianne Santaguida • Aleksandar Savic, Professor, MD • Mary Lynn Savoie, MD • Michael Savona, MD, FACP • Hamid Soyar, MD • Dale Schaar, MD, PhD • Gary Schiller, MD • John Seymour, MD • Richard K. Shadduck, MD • Paul J. Shami, MD • Jamile Shammo, MD, FACP, FACP • Lee-Yung Shih, MD • Akiko Shimamura, MD, PhD • Jake Shortt, MD • Barry Skikne, MD, FACP, FCP[SA] • Katja Sockel, MD • Kellie Sprague, MD • Lisa Sprot, MD • Aspasia Stamatioullas, MD • Reinhard Sauter, MD • Argris Symeonidis, MD • James Thompson, MD • Swapna Thota, MD • Raoul Tipes, MD, PhD • Hwei Fang Tien, MD • Hongyan Tong, MD • Zuzana Tothova, MD, PhD • Thu Le Trinh, MD • David Valcárcel, MD, PhD • Amit Verma, MD • Norbert Vey, MD • Carlos Viol, MD • Athina Vinickest, MD • Sara von Bahr Grebakk, MD • Maria Teresa Voso, MD • Alison Walker MD, MPH • Erika Warlick, MD • Alan Warren, MD, PhD • Richard Wells, MD • Dan Wiseman, MD • Zhijian Xiao, MD • Yumi (Yamamoto) Ogata, BA • Karen Yee, MD • Cecilia Yi, MD • Yataro Yoshida, MD • Ling Zhang, MD

Clinical Studies – Research – Education

Please help us continue to inspire and encourage more!

Every membership counts!

Please help the MDS Foundation share and promote these efforts!

Please join today!

www.mds-foundation.org/membership

Together, we are community resource of Hope for those living with MDS.
THINKING OF JOINING THE MDS FOUNDATION AS A CHANGING THE FUTURE OF MDS MEMBER?

To join the MDS Foundation and help us fulfill our mission of moving closer to a cure for MDS, please visit our website at https://www.mds-foundation.org/changing-the-future-of-mds-membership.

BENEFITS OF MEMBERSHIP

• You are part of the solution to change MDS outcomes. Your membership fee helps support global physician and patient educational initiatives, and helps to empower patients with courage and hope.
• Updates on the status of our Global Centers of Excellence and their live patient and family forum events that allow for more rapid dissemination of new research and treatment developments.
• Information on the latest clinical trials to potentially share or participate in.
• Access to MDS awareness materials to share with family and friends.
• Opportunities to participate in or host support group events with your friends & community.
• Receive two printed issues of The MDS News, which includes the latest on MDS research as well as inspiring patient and caregiver stories.

CURRENT CHANGING THE FUTURE OF MDS MEMBERS: Camille Abboud, MD • Andrew Adams Aref Al-Kali, MD • Sharon N. Allison • Rodney Armstrong Jr. • Kimo Bachiashvili, MD • Roy Bennett • Robert Bills • Rena Buckstein, MD, FRCPC • Victor Chang, MD, FACP • June-Won Cheong, MD • Laurence Cove and Ann Brody Cove • Patricia Collins • Renee Conrad • Magdalen Czader, MD, PhD • Mark and Martha De Noble James and Josephine Diedrich • Sally Ferguson • Chun Yew Fong, MD • James M. Foran, MD • Roman Suarez Garcia • Andrew Glasgow • Janice Gottlieb • Stuart L. Goldberg, MD • Andrea Greene • Lee Harris • Theron and Brooke Hatch • David Hinton • Michel Hoesly, MD • Ishmael Jaiyesimi, MD • Lou and Kathy Jerge • Diane Jordan • Michael Kenneth Keng, MD • Lisa Kick • Jeffery Klco, MD • Roger Kloeppping • Marilee Korsinen • Curtis E. Lang • Cathy Layton • Christine Lee • Gene Lynes Frederic and Kathleen Levensen • G Malcolm Louden • Roger M. Lyons, MD, FACP • Joe Maloney • David Mandell • Gerald and Phyllis Mandell • Sheila L. Martin • Susan Martin • Daniel McCormick • Robert McElveen • William McGovern • Julia McGuire • Jacquelyn Mertens • Michele A. Metropolis • DeAnn Miller • Betty Jane Mincemoyer • Joseph O. Moore, MD • Deborah J. Peirce • James Phillips Raal • J. Puertollano Jun Qian, MD • Brandi Reeves • Lorne Ruby • Raymond J. Seiler • Walt Smith • John Stasenko • Joseph Strothers • Swapna Thota, MD • Theresa Tintor • Lisa Tomczykowski • Janet B. Warfield Carolyn Webb • Stephen Francis Weber • Michael Weiner • Leon Weiss • JoEllen White • Kenan White • Cecilia Arana Yi, MD • Leonard Yool

FIND THE TRUSTED RESOURCES YOU NEED...

You or someone you know has been diagnosed with MDS

Hearing the words Myelodysplastic Syndromes or MDS can be frightening. The diagnosis of MDS is often unexpected and filled with both immediate and long-term challenges. You probably have many questions. Have you accessed your complete set of tools to prepare, participate, and LIVE with MDS?

Dealing with MDS can be very difficult, but it helps to have helpful resources that are reliable and that you can trust.

To order your FREE copy of our resources available in multiple languages, please visit our website: https://www.mds-foundation.org/material-order-form-4/
2019 PATIENT FORUMS

MARK YOUR CALENDAR FOR THE LOCATION NEAREST YOU!

- **FEBRUARY 2**
  Los Angeles, CA

- **MARCH 9**
  Phoenix, AZ

- **MARCH 30**
  Jacksonville, FL

- **APRIL 27**
  Pittsburgh, PA

- **MAY 11**
  Copenhagen, Denmark

- **JUNE 22**
  Baltimore, MD

- **JULY 20**
  Iowa City, IA

- **AUGUST 10**
  Seattle, WA

- **SEPTEMBER 19**
  Nashville, TN

- **OCTOBER 12**
  Westwood, KS

- **NOVEMBER 9**
  Dallas, TX

LEARN MORE AT:
www.mds-foundation.org/patient-and-family-forums

Many patients and caregivers have never met another person diagnosed with MDS until they connected with them at one of our forums. If you’ve never attended one, you won’t want to miss this opportunity to meet others and to learn more about MDS, current treatments, and emerging therapies from leading experts. Not only will you find answers, support and hope for MDS but you will learn tips and strategies for patients and caregivers LIVING with MDS.

PLEASE MAKE SURE TO REGULARLY CHECK OUR WEBSITE FOR MEETINGS TAKING PLACE IN A CITY NEAR YOU!
YOU AND MDS

AN ANIMATED PATIENT’S GUIDE TO MYELODYSPLASTIC SYNDROMES

We are excited to announce the MDS Foundation’s new online patient education resource, titled “You and MDS: An Animated Patient’s Guide to Myelodysplastic Syndromes”.

This resource is intended for patients with MDS, as well as family members and caregivers. You will find expert advice about MDS to help you discuss key issues with your health care provider and make important decisions related to management and treatment. Easy-to-understand animations with audio narration, expert video explanations, patient interviews, illustrated slide shows, and educational downloads are available to you. You are invited to provide feedback to help direct future content as this site becomes part of your personal information resource on MDS. We welcome you to this online community resource to improve your quality of life and health outcomes.

New educational content to be added to Animated Patient’s Guide to MDS – www.YouAndMDS.com. In partnership with Mechanisms in Medicine (MIM) we are creating additional educational content on MDS and erythropoiesis-stimulating agents to address needs related to better patient understanding on the importance of erythroid maturation defects, and therapeutic advances as this responds to the needs of a subgroup of MDS patients.

YOU AND ANEMIA:
An Animated Patient’s Guide to Myelodysplastic Syndromes — RBC Mechanisms and Maturation in Erythropoiesis — Abbreviated Title: MDS and Anemia

Coming soon!

YOU AND AML

An Animated Patient’s Guide to Acute Myeloid Leukemia

Learn more at www.YouAndMDS.com

Animated Patient Education Resources to be hosted on www.MDS-Foundation.org
CELGENE CORPORATION AND ACCELERON PHARMA ANNOUNCE SUBMISSION OF LUSPATERCEPT BIOLOGICS LICENSE APPLICATION TO US FDA

SUMMIT, NJ & CAMBRIDGE, MASS., APRIL 5, 2019 (BUSINESS WIRE) –

- BLA submission includes both myelodysplastic syndromes and beta-thalassemia indications
- EMA marketing application for both indications planned for Q2:19

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

The submission is based on the safety and efficacy results of the pivotal phase 3 studies MEDALIST and BELIEVE, both recently presented at the American Society of Hematology annual meeting, where MEDALIST was included in the plenary session.

“There remains a high unmet medical need for patients with MDS or beta-thalassemia who suffer from the effects of their disease-related anemia. The primary treatment option for these patients currently is chronic transfusion of red blood cells which can be associated with complications such as iron overload,” said Jay Backstrom, MD, Chief Medical Officer for Celgene. “New treatment options are urgently needed for these patients. With this submission, we look forward to working with the Agency to deliver luspatercept to patients with these serious blood diseases.”

The companies also plan to submit a marketing application to the European Medicines Agency in the second quarter of 2019.

“The BLA submission is a key milestone for Acceleron and a credit to our longstanding collaboration with Celgene,” said Habib Dable, President and Chief Executive Officer of Acceleron. “We believe luspatercept’s positive clinical trial results demonstrate its potential as a novel treatment for patients with lower-risk MDS as well as in beta-thalassemia. All involved have worked diligently to develop luspatercept for patients with chronic anemias associated with these serious blood disorders.”

Luspatercept is an investigational therapy that is not approved for any use in any country for any indication.

About Luspatercept

Luspatercept is a first-in-class erythroid maturation agent (EMA) that regulates late-stage red blood cell maturation. Acceleron and Celgene are jointly developing luspatercept as part of a global collaboration. A phase 3 trial (COMMANDS) in ESA-naive, lower-risk MDS patients, the BEYOND phase 2 trial in non-transfusion-dependent beta-thalassemia, and a phase 2 trial in myelofibrosis are ongoing. For more information, please visit www.clinicaltrials.gov.

About MEDALIST

MEDALIST is a phase 3, randomized, double blind, placebo-controlled, multicenter study evaluating the safety and efficacy of luspatercept in adults with very low, low-, or intermediate-risk myelodysplastic syndromes (MDS). All patients were RBC transfusion dependent and were either refractory or intolerant to prior erythropoiesis-stimulating agent (ESA) therapy or were ESA naïve with endogenous serum erythropoietin ≥ 200 U/L and had no prior treatment with disease modifying agents. The median age of the patients enrolled in the trial was 71 years in the luspatercept treatment group and 72 years in the placebo group. Median transfusion burden in both treatment arms was 5 RBC units/8 weeks. 229 patients were randomized to receive either luspatercept 1.0 mg/kg (153 patients) or placebo (76 patients) by subcutaneous injection once every 21 days. The study was conducted at 65 sites in 11 countries.

About BELIEVE

BELIEVE is a phase 3, randomized, double blind, placebo-controlled multicenter study comparing luspatercept + best supportive care (BSC) versus placebo + BSC in adults with beta-thalassemia patients who require regular RBC transfusions. The median age of the patients was 30 years in both treatment arms. 336 patients were randomized to receive either luspatercept 1.0 mg/kg (224 patients) or placebo (112 patients) by subcutaneous injection every 21 days for up to 48 weeks. Crossover to the luspatercept treatment groups was allowed after unblinding based on the recommendation of an independent Data Safety Monitoring Committee; patients treated with luspatercept will be followed for up to 3 years. The study was conducted at 65 sites in 15 countries.
CELGENE CORPORATION ANNOUNCES KEY REGULATORY UPDATES FOR REVLIMID® IN LYMPHOMA AND LUSPATERCEPT IN MDS AND BETA-THALASSEMIA

• US FDA grants Priority Review for REVLIMID® (lenalidomide) in combination with rituximab (R²) for previously treated follicular and marginal zone lymphoma
• Prescription Drug User Fee Act action date set for June 27, 2019
• Luspatercept Biologics License Application (BLA) submission timing updated to April 2019

SUMMIT, NJ (BUSINESS WIRE) (2/26/2019) — Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the company’s supplemental New Drug Application (sNDA) for REVLIMID® (lenalidomide) in combination with rituximab (R²) for the treatment of patients with previously treated follicular and marginal zone lymphoma. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set its action date as June 27, 2019.

“R² has the potential to offer patients with previously treated follicular lymphoma and marginal zone lymphoma a chemotherapy free option” said Jay Backstrom, MD, Chief Medical Officer and Head of Global Regulatory Affairs for Celgene. “We look forward to working with the FDA to bring the R² regimen to patients as quickly as possible.”

The sNDA is based on results from the randomized, double-blind, phase 3 AUGMENT study, which evaluated the efficacy and safety of the investigational R² combination versus rituximab plus placebo in patients with relapsed/refractory follicular and marginal zone lymphoma. Results from the study were presented at the 2018 American Society of Hematology (ASH) Annual Meeting and Exposition.

Earlier this year, Celgene submitted and had accepted a Marketing Authorization Application (MAA) for R² to the European Medicines Agency (EMA) for the treatment of relapsed/refractory follicular and marginal zone lymphoma.

REVLIMID alone or in combination with other agents is not approved for use in follicular lymphoma or marginal zone lymphoma in any geography.

Celgene also announced updated timing for the anticipated submission of a Biologics License Application (BLA) with the U.S. FDA for luspatercept in adult patients with anemia related to very low to intermediate myelodysplastic syndromes (MDS) with ring sideroblasts who require red blood cell transfusions, and in adult patients with anemia related to beta-thalassemia who require regular red blood cell transfusions. The company expects to submit the BLA in April 2019.

About Revlimid

REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of patients with multiple myeloma (MM). It is indicated as maintenance therapy in patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID® is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. It is indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID® is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

DOWNLOAD OUR MOBILE APPS!

MDS FOUNDATION

HAVE MDS INFORMATION AT YOUR FINGERTIPS!
• Find an MDS Center of Excellence near you
• View upcoming events, order patient materials, and more...

DOWNLOAD TODAY!

MDS MANAGER

EFFECTIVELY MANAGE YOUR MDS CARE

MDS Manager™ is a newly developed mobile app for smartphones and tablets! This app includes a variety of features to assist patients and their caregivers living with MDS to more effectively manage their care, improve communication with providers, and track their response to treatment.
DAIICHI SANKYO INITIATES FIRST NOVEL COMBINATION STUDY OF TWO INVESTIGATIONAL AGENTS WITHIN ITS AML FRANCHISE IN PATIENTS WITH AML

TOKYO, MUNICH AND BASKING RIDGE, NJ (12/19/2018) –

• Phase 1 study initiated to evaluate the combination of a FLT3 inhibitor, quizartinib, and an MDM2 inhibitor, milademetan (DS-3032), in patients with relapsed/refractory FLT3-ITD AML or newly-diagnosed FLT3-ITD AML unfit for intensive chemotherapy
• Expansion of an ongoing phase 1 study to evaluate the combination of milademetan and 5-azacitidine, an inhibitor of DNA methylation, is also underway in AML and high-risk MDS
• The AML Franchise of Daiichi Sankyo is evaluating multiple investigational agents as single agents and in combination to further advance the treatment of patients with AML. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the first patient has been dosed in the first novel-novel combination study evaluating two investigational agents within its AML Franchise. The phase 1 study will evaluate the safety and activity of the combination of a FLT3 inhibitor, quizartinib, and an MDM2 inhibitor, milademetan (DS-3032), in patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML) or newly-diagnosed FLT3-ITD AML unfit for intensive chemotherapy, a very aggressive form of the disease associated with poor prognosis.

“We have initiated this combination study of quizartinib and milademetan in order to determine the safety and tolerability of the combination and if the addition of the MDM2 inhibitor milademetan may potentially further improve the outcomes of patients with relapsed/refractory FLT3-ITD AML beyond what has been previously reported with single agent quizartinib,” said Arnaud Lesegretain, Vice President, Oncology R&D and Head, AML Franchise, Daiichi Sankyo. “In this study, we also are exploring the potential of the combination of quizartinib and milademetan in patients with newly-diagnosed FLT3-ITD AML who are unfit for intensive chemotherapy. This study is the first of several planned studies that will evaluate the potential of novel combinations within our investigational AML Franchise, as we are committed to continuously improving the standard of care for patients with AML.”

Quizartinib is the first FLT3 inhibitor to demonstrate a survival benefit as an oral, single agent compared to chemotherapy in a randomized, phase 3 study (QuANTUM-R) in patients with FLT3-ITD AML, which was refractory or relapsed within six months of first remission, and single agent milademetan has demonstrated preliminary clinical activity in AML and myelodysplastic syndrome (MDS) in a phase 1 study.1,2 Additionally, preclinical research has shown that the combination of quizartinib and milademetan has greater activity in FLT3-ITD AML cells compared to the respective single agent treatments.3

In the QuANTUM-R study, the median treatment duration with quizartinib was 4 cycles of 28 days each versus 1 cycle in the salvage chemotherapy arm. Incidence of treatment-emergent adverse events was comparable between patients who received single agent quizartinib and those who received salvage chemotherapy. The most common adverse drug reactions (>30 percent, any Grade) in patients treated with quizartinib included infections, bleeding, nausea, asthenic conditions, pyrexia, febrile neutropenia and vomiting, and the most common Grade ≥3 adverse drug reactions (>20 percent) were...
infection and febrile neutropenia. The most common laboratory adverse reactions (incidence >50 percent) were decreased white blood cell count, decreased lymphocyte count, decreased hemoglobin, decreased neutrophil count and decreased platelet count. The safety profile observed in QuANTUM-R appears consistent with that observed at similar doses in the quizartinib clinical development program.

In addition to the quizartinib and milademetan combination study, an ongoing phase 1 study of milademetan has been expanded to include evaluation of milademetan in combination with the hypomethylating agent 5-azacitidine, an inhibitor of DNA methylation, in patients with newly-diagnosed AML unfit for intensive chemotherapy, relapsed/refractory AML or high-risk MDS.

About the Quizartinib/Milademetan Combination Study

The multi-center, non-randomized, phase 1, open-label, two-part study is investigating the safety and efficacy of milademetan as a single agent and in combination with the hypomethylating agent 5-azacitidine. The first part of the study (dose escalation) will evaluate the safety and tolerability and identify the maximum tolerated dose and recommended dose for expansion of milademetan as a single agent and in combination with 5-azacitidine in patients with relapsed/refractory AML or high-risk MDS. The second part of the study (dose expansion) will confirm the safety and tolerability at the recommended dose of milademetan in combination with 5-azacitidine and will identify a recommended phase 2 dose in patients with relapsed/refractory AML, newly-diagnosed AML unfit for intensive chemotherapy or high-risk MDS. The primary objectives of the study are safety and tolerability, maximum tolerated dose, recommended dose for expansion and response to treatment. Key secondary objectives include evaluation of pharmacokinetics and pharmacodynamic effects. The study is expected to enroll up to 200 patients in the U.S. For more information about the study, visit ClinicalTrials.gov.

About Quizartinib

Quizartinib, the lead investigational agent in the AML Franchise of the Daiichi Sankyo Cancer Enterprise, is an oral selective type II FLT3 inhibitor currently in phase 3 development for relapsed/refractory FLT3-ITD AML (QuANTUM-R) in the U.S. and EU; phase 3 development for newly-diagnosed FLT3-ITD AML (QuANTUM-First) in the US, EU and Japan; phase 2 development for relapsed refractory FLT3-ITD AML in Japan; and phase 1 development in combination with an investigational agent, milademetan, for relapsed/refractory FLT3-ITD AML and newly-diagnosed FLT3-ITD AML unfit for intensive chemotherapy in the US, EU and Japan.

Quizartinib has been granted Priority Review and Breakthrough Therapy designation for the treatment of adult patients with relapsed/refractory FLT3-ITD AML, and Fast Track designation for the treatment of relapsed/refractory AML by the US Food and Drug Administration (FDA). Quizartinib also has been granted accelerated assessment by the European Medicines Agency (EMA) for the treatment of adults with relapsed or refractory AML, which is FLT3-ITD positive, and granted Orphan Drug designation by both the FDA and the European Commission (EC) for the treatment of AML and by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of FLT3-mutated AML.

About Milademetan

Milademetan (DS-3032) is an oral selective MDM2 inhibitor currently in phase 1 clinical development for solid and hematologic malignancies, including a combination study with quizartinib in relapsed/refractory FLT3-ITD AML or newly-diagnosed FLT3-ITD AML unfit for intensive chemotherapy in the US, EU and Japan; a single agent and combination study with 5-azacitidine in newly-diagnosed AML unfit for intensive chemotherapy, relapsed/refractory AML or high-risk MDS in the US; and two single agent studies in lymphomas and solid tumors in the U.S. and Japan.

Quizartinib and milademetan are investigational agents that have not been approved for any indication in any country. Safety and efficacy of these investigational agents have not been established.

References

AGIOS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR TIBSOVO® (IVOSSIDENIB) IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION IN ADULT PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

CAMBRIDGE, MASS., MARCH 26, 2019 (GLOBE NEWSWIRE) -

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TIBSOVO® (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

“Outcomes for newly diagnosed AML patients ineligible for intensive chemotherapy are still poor, and there are no approved options specifically for patients with an IDH1 mutation,” said Chris Bowden, MD, chief medical officer at Agios. “The Breakthrough Therapy designation provides further support that combining azacitidine and ivosidenib for these patients has the potential to be a compelling treatment option.”

The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a drug candidate that is planned to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on one or more clinically significant endpoints.

Results from the Phase 1/2 study of ivosidenib in combination with azacitidine were last presented at the 17th International Symposium on Acute Leukemias in Munich. In the ivosidenib arm of the Phase 1b portion of the study, 23 patients received 500 mg of ivosidenib daily plus azacitidine. The median age was 76 years old, and 52% of patients were age 75 or older. The safety profile of combination therapy remains consistent with the safety profile of ivosidenib and azacitidine alone in this patient population. As of the August 1, 2018 data cutoff, mean neutrophil and platelet counts were maintained near or above thresholds for complete response (CR) with partial hematologic recovery (CRh) while on study treatment with ivosidenib and azacitidine. Overall, 78% (18/23) of patients had a response and 57% (13/23) of patients had a CR. The median duration of CR had not been reached (95% CI 7.7, NE). In addition, the 12-month survival rate was 82%.

Ivosidenib is not approved in any country for the treatment of patients with newly diagnosed AML or approved in combination with azacitidine.

About TIBSOVO® (ivosidenib)

TIBSOVO® (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test. For more information, visit TIBSOVO.com.

IMPORTANT SAFETY INFORMATION

WARNING: DIFFERENTIATION SYNDROME

Patients treated with TIBSOVO have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.

WARNINGS AND PRECAUTIONS

Differentiation Syndrome: See Boxed WARNING. In the clinical trial, 19% (34/179) of patients with relapsed or refractory AML treated with TIBSOVO experienced differentiation syndrome. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated. Symptoms of differentiation syndrome in patients treated with TIBSOVO included noninfectious leukocytosis, peripheral edema, pyrexia, dyspnea, pleural effusion, hypotension, hypoxia, pulmonary edema, pneumonitis, pericardial effusion, rash, fluid overload, tumor lysis syndrome, and creatinine increased. Of the 34 patients who experienced differentiation syndrome, 27 (79%) recovered after treatment or after dose interruption of TIBSOVO. Differentiation syndrome occurred as early as 1 day and up to 3 months after TIBSOVO initiation and has been observed with or without concomitant leukocytosis.

If differentiation syndrome is suspected, initiate dexamethasone 10 mg IV every 12 hours (or an equivalent dose of an alternative oral or IV corticosteroid) and hemodynamic monitoring until improvement. If concomitant noninfectious leukocytosis is observed, initiate treatment with hydroxyurea or leukapheresis, as clinically indicated. Taper corticosteroids and hydroxyurea after resolution of symptoms and administer corticosteroids for a minimum of 3 days. Symptoms of differentiation syndrome may recur with premature discontinuation of corticosteroid and/or hydroxyurea treatment. If severe signs and/or symptoms persist for more than 48 hours after initiation of corticosteroids, interrupt TIBSOVO until signs and symptoms are no longer severe.

QTc Interval Prolongation: Patients treated with TIBSOVO can develop QT (QTc) prolongation and ventricular arrhythmias. One patient developed ventricular fibrillation attributed to TIBSOVO. Concomitant use of TIBSOVO with drugs known to prolong the QTc interval (e.g., anti-arrhythmic medicines, fluoroquinolones, triazole anti-fungals, 5HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Conduct monitoring of electrocardiograms (ECGs) and electrolytes. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or in those who are taking medications known to prolong the QTc interval, more frequent monitoring may be necessary.

Interrupt TIBSOVO if QTc increases to greater than 480 msec and less than 500 msec. Interrupt and reduce TIBSOVO if QTc increases to greater than 500 msec. Permanently discontinue TIBSOVO in patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia.

Guillain-Barré Syndrome: Guillain-Barré syndrome occurred in <1% ([2/258]) of patients treated with TIBSOVO in the clinical study. Monitor patients taking TIBSOVO for onset of new signs or symptoms of motor and/or sensory neuropathy such as unilateral or bilateral weakness, sensory alterations, paresthesias, or difficulty breathing. Permanently discontinue TIBSOVO in patients who are diagnosed with Guillain-Barré syndrome.

Please see full Prescribing Information, including Boxed WARNING.
What is acute myeloid leukemia?

Acute myeloid leukemia (AML) is a kind of cancer that affects the blood and bone marrow. It is the most common form of acute leukemia in adults. AML is characterized by the rapid production and growth of abnormal blood cells, which can build up in the bone marrow and prevent the production of normal blood cells. The most common signs and symptoms of AML include shortness of breath, bruising, fever, weakness, and infection.
Daiichi Sankyo Cancer Enterprise

The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by three pillars we aim to deliver seven distinct new molecular entities over eight years during 2018 to 2025:

- Antibody Drug Conjugate Franchise
- Acute Myeloid Leukemia Franchise
- Breakthrough Science

Our powerful research engines include:
- Two laboratories for biologic/immuno-oncology and small molecules in Japan
- Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA

For more information, please visit: www.DSCancerEnterprise.com.

The Acute Myeloid Leukemia (AML) Franchise of the Daiichi Sankyo Cancer Enterprise

The AML Franchise is pushing the boundaries of science aiming to define a new standard of care for patients with AML, a fast-growing form of leukemia that has the lowest five-year survival rate of all leukemias. Advancements in the understanding of the molecular biology of AML are creating opportunities for our researchers to discover and develop therapies that target the underlying drivers of the disease.

For more than 30 years, the standard of care for the treatment of AML went unchanged in part due to the complex biology of AML. While a few new treatments have been approved recently, there is still significant unmet need and much work to be done to continue to expand the treatment options available for patients with AML. Our investigational AML Franchise is evaluating a portfolio of therapies that leverage three distinct strategies for the treatment of AML. Our investigational AML Franchise will evaluate combination regimens including these and other compounds for their potential to change the standard of care for patients with AML.

Daiichi Sankyo’s Obligation & Commitment

We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. As an anchor in the Daiichi Sankyo Cancer Enterprise, significant investment and resources have been committed to the investigational AML Franchise. The formation of the investigational AML Franchise underscores our commitment to understanding AML tumor biology and developing therapies that improve the depth and quality of responses by targeting AML on multiple fronts. Combination regimens, which may address the heterogeneity and polyclonality of the disease, may be key to changing the standard of care for AML. With a portfolio of compounds that target different AML drivers, our investigational AML Franchise is an ideal platform in which to study various combination therapies.

Daiichi Sankyo’s Partnerships & Collaborations

Daiichi Sankyo Cancer Enterprise is actively pursuing partnerships and collaborations with experts and academic centers worldwide to help advance the science of AML. A collaboration with MD Anderson Cancer Center, one of the largest integrated leukemia centers worldwide, is focused on accelerating the development of novel therapies for AML. Multiple phase 1 and 2 clinical trials, led by MD Anderson, will be launched to evaluate our investigational compounds and multiple agents in combination regimens.

Incorporation of translational work, including exploration of novel biomarkers, as well as preclinical studies of new agents, is aimed at improving our understanding of mechanisms of resistance to existing and emerging treatments.

Daiichi Sankyo’s Relentless Focus on Transforming Science

Molecular subtyping (classifying tumors into distinct categories based on molecular features) is creating new scientific opportunities to better understand the science behind AML and improve on current treatment options. Our investigational AML Franchise is currently developing a portfolio of therapies that leverage three distinct strategies. Pursuing multiple pathways and studying these investigational compounds in combination with other therapies may potentially enable us to deliver more effective treatment options and expedite development to reach patients sooner.

Our investigational AML Franchise is currently developing a portfolio of therapies that leverage three distinct strategies:

- Growth Factor Receptor Inhibition (FLT3 inhibitor)
- Tumor Suppressor p53 Reactivation (MDM2 inhibitor)
- Targeting Epigenetic Regulation (dual EZH1/EZH2 inhibitor, BRD4 inhibitor and IDH1 inhibitor)
Celgene is researching the following objectives in patients with MDS, Idiopathic Cytopenias of Undetermined Significance (ICUS) and AML:

- Current and evolving patterns for diagnosing, treating, and monitoring patients
- Outcome measures
- How routine practice compares to national treatment guidelines
- Treatment patterns and outcomes in patients with del(5q), with or without additional cytogenetic abnormalities
- Association of patient characteristics, treatment regimens and clinical outcomes with patient-reported Health Related Quality of Life (HRQoL) and economic outcomes
- Clinical outcomes based on treatment in patients with or without mutations
- Correlation between mutation detection/allele burden in bone marrow and peripheral blood samples
- Molecular and/or cellular marker’s relation to prognostic classification, drug mechanism of action and clinical and treatment outcomes

Select eligibility criteria:

- Newly diagnosed,* primary or secondary MDS, ICUS or AML
- MDS/ICUS patients must be at least 18 years
- AML patients must be at least 55 years of age
- Patients must be willing and able to complete enrollment and follow-up HRQoL instruments; and therefore proficient in either English or Spanish

*To be considered “newly diagnosed,” the diagnosis must have been confirmed no more than 60 days prior to the date the patient signs the informed consent (ICF) documents.

Note: Concomitant patient enrollment in other studies is permitted.
**MYELODYSPLASTIC SYNDROMES (MDS) BY THE NUMBERS**

Myelodysplastic syndromes (MDS) are an often unrecognized, underdiagnosed rare group of bone marrow failure disorders, where the body no longer makes enough healthy, normal blood cells in the bone marrow. The disease is also known as a form of blood cancer.

- **12-20K** new cases of MDS are reported every year in the U.S., with an average of **33-55** people diagnosed in the U.S. every day.  

- **60-170K** people are estimated to live with MDS in the U.S. with an estimated **87,000** new cases each year worldwide.

- **75%** of MDS patients are **60+** years of age, and the disease also can affect **children and young adults**.

- **MDS patients (or 30%)** progress to acute myeloid leukemia (AML).

- **1 out of 3** MDS patients (or 30%) progress to acute myeloid leukemia (AML).

- The average survival rate for lower risk patients (who do not receive a bone marrow transplant) is **approximately 5 months** for high-risk patients.

**Learn more about the MDS Awareness Walks and additional information about MDS.**

www.mds-foundation.org

---


MY DIAGNOSIS...

SHERRY PRATT
Ridgeland, Mississippi

Someone once said, “Life is what happens to you when you make other plans”. I have learned that statement is so very true.

I NEVER thought I would ever get a cancer diagnosis. I taught exercise classes, walked every day, ate a Mediterranean diet, paid attention to the products I used, and the food I ate. I even became a certified Health Coach and taught healthy living classes.

But I did get a cancer diagnosis; a rare blood cancer called Myelodysplastic Syndromes (MDS). My specific subtype is Refractory Anemia with Ringed Sideroblasts (RARS). This affects the red blood cells and has no cure, except for a stem cell transplant (also called a bone marrow transplant).

At first, I was scared, mad, confused, and in denial. Then I decided that if David faced a giant called Goliath and was not defeated, I could too. God is still in the miracle business, and I began to strengthen my faith by staying in the Word. You know you cannot learn a foreign language well by practicing and listening to your studies only on Sunday morning. You must stay in the Word of God daily. It is His medicine.

Every day, all day, I would say a silent prayer, “Thank you Jesus for my healing.” I read Bible verses every day that were about healing. My friend Millie put a small booklet of those verses together for me on a flipchart. I still read those verses every day. My husband framed them and we placed them all over my home, so I would see them all the time. I put pictures of healthy red blood cells all over my home too, so I could visualize them — I even have that picture as my background wallpaper on my phone. I submersed myself in God’s word. I purchased a new Bible that had weekly devotions in it for the year of 2016 — the Year of Jubilee (Rod Parsley Jubilee Bible).

When I was first diagnosed on August 19, 2014, my hemoglobin was in the 9’s (normal is 12–18). I was told I would be given various therapies to help raise my red blood cell count, so I could function properly. I sought a second opinion in New Orleans at Ochsner’s. They told me I could get a stem cell transplant eventually, but that my disease is one that would be treated with differing therapies and drugs. Several of those were used to no avail, and by the time September 2016 rolled around, my hemoglobin had dropped into the 7’s.

I took a drug called lenalidomide (Revlimid®), which was very expensive and did not work. The epoetin alfa (Procrit®) shots I got every Tuesday would raise my red blood cells for a couple of days, but not continually. By the time the next Tuesday rolled around, my labs would show that my counts were about the same or sometimes even lower.

I had reluctantly agreed to a drug therapy called azacitidine (Vidaza®). It is a hypomethylating agent that helps to increase your red blood cell counts. I was to take a 1-hour drip of this 5 days a month, for 5 years. It was not a cure, just a crutch. I was 62 when this would begin and in five years, I would be 67 — older and probably much sicker. I asked my doctor what happens at the end of five years and he said, “You will have to go somewhere to get a stem cell transplant.”

I was scheduled to begin the azacitidine (Vidaza®) infusions on August 29, 2016. The Wednesday before, my dear friend Susan asked me if I had ever thought about the Cancer Treatment Centers of America (CTCA)? Frustrated at the whole situation I just told her no. I start azacitidine (Vidaza®) the next week and left it at that. On the Friday before the 29th of August, I was taking a nap on the couch and woke up to a Cancer Treatment Center of America commercial on TV. Something just tugged at my heart and I called the number. It was the first of many miracles that God would bestow on me in the next 12 months.

Day Zero – Sherry with her donor, her sister Sonya, and sister Sheila.
The first miracle happened the next morning when I called my siblings and asked their opinion on what I should do. My younger sister Sonya said to cancel the Vidaza and go to Chicago (Zion, Illinois) for a third opinion. God knew all along that Sonya would be a KEY player in my recovery.

On September 12, Wally and I were in Zion at the CTCA for the first time. When we walked into the foyer of the hospital, there were people everywhere asking if you needed help. There was a lady on the second floor of the foyer playing “Amazing Grace” on a grand piano. I was touched by this place. It did not resemble a hospital at all. I could feel the love and peace in the atmosphere. I had read my devotion that morning and it said “Today you are marked for a miracle.”

All during the week, God was literally walking the halls with us. We met so many people who had been told by their local physicians to go home and get their affairs in order – they wouldn’t live over 6 months. Some of those people were there for their annual checkups after 12 years.

When I first met with my doctor, he explained my disease in great length and he looked at me and paused... I was going to ask him what he would recommend if I were his mother, but he beat me to it. He told me “If you were my mother, I would do a stem cell transplant so you can have many more years of quality life.” Cold chills ran down my spine. Little did I know at that point the standard of care used at CTCA is coined the Mother Standard of Care. Everyone from the doctors, to nurses, to janitors and food service workers treat you as if you were their mother. They also include a naturopathic doctor and nutritionist to minister to your care while you are there. They know that your attitude during a cancer diagnosis is key to your healing.

Once we decided to treat there, I had my blood tested daily. My doctors at CTCA wanted to try a medication called Decitabine (Dacogen®). It was a drug much like azacitidine (Vidaza®), and it too increased red blood cells in some patients. I took 5 days of that drug and flew home on the 20th of September with lots of instruction on what to do if I started a fever or if my numbers began to drop.

They did drop drastically within the next week. I was hospitalized twice with fever and had blood cultures done. I took lots of antibiotics and had platelet and blood transfusions. The hospitals in my hometown were not equipped for a neutropenic patient, and I begged my doctors at CTCA to allow me to return. I returned to CTCA on October 8, 2016 and never left there until my transplant and 100 days were over.

We discussed possible donors for me. They began looking for donors on the worldwide registry. They inquired about my siblings, but decided they may have been too old to donate.

The second week at CTCA my devotion was from 1 Cor 2:12 — Now we have received not the spirit of the world, but the spirit which is of God, so that we might know the things that are freely given to us by God. I wasn’t meant to wonder where my help would come from, I took hold of what God had to offer... healing...

My devotions continued to lift me each week. Isaiah 41:10 Do not fear for I am with you; do not be dismayed for I am your God, I will strengthen you, I will help you, yes I will uphold you with my righteous right hand.

My fourth week at CTCA my devotion was entitled “The Cure”. He knows how to treat the broken-hearted patient, the anxious patient. He knows how to treat the scared patient. He is the cure. He cures physical illness and disease. Your Bible is full of examples. Jesus’ cures are real today.

By that time, I had met with the head of the stem cell unit and he said he wanted to test my younger sister Sonya to see if she might be a match. She was 55, just 6 years younger than I. I was elated that they wanted to do this, but anxious for her. She agreed wholeheartedly, and they sent her a blood testing kit.
On November 3rd, my devotion was entitled “Anointed Vessels”. I learned an example of the tangible transfer of God’s anointing is found in Acts 5. There the lame and sick were placed in the street so that the shadow of Peter would fall on them as he passed. Just his shadow transferred the anointing of God. These things did not just happen in Jesus’ day. They happen today. On November 3rd we were told my younger sister Sonya was a 100% match for my stem cells. (There is only a 25% chance a sibling will be a 100% match). Her stem cells would physically make me whole again, and they would be transferred to me. God knew when he knit her in my mother’s womb 55 years ago, as He would be using her stem cells to sustain my life.

What is even more amazing is that Sonya was our family’s accident baby. There are no coincidences with God. No accidents. He is always working behind the scenes.

On December 27th, my devotion was about how God delights in blessing you with miracles. That week I entered the hospital for the transplant. I was in for conditioning chemo, where they would give me 3 kinds of chemo to kill my diseased stem cells — at least most of them — to make way for my donor cells. A week after the chemo infusions, I got very ill. It was also the time I would get my new donor stem cells. Through the sickness, I continued to pray the Lord’s prayer, read my healing verses, and say thank you to Jesus for my healing. I had that peace that passes all understanding. God was in control, not me.

On January 3, 2017, I received 7.69 million stem cells from my little sister Sonya. I had received my miracle.

We are now actually twins but not identical... 6 years apart!!! The next 28 days were not so easy. I got Cdiff from all the antibiotics I had taken, I was very weak some days, and in general felt bad. But I tried my best to persevere through the bad feelings. I walked the halls every day, because I knew I had to keep my strength up. There were even some days I don’t remember. I got fevers a couple of times, and some mouth sores. Luckily, my caregivers kept a meticulous journal about my condition each day. This helped me tremendously to recount what I went through. I repeated “Thank you Jesus for my healing” every day all day, and I recited the Lord’s prayer.

The anointing of God’s Holy Spirit can cool the fevered brow of an infant child, cause blindness to disappear, cancer to cease it’s destruction, finances to increase and favor to become your constant companion... My hope for each of you today is that through prayer you have had a personal conversation with God confessing your sins, and asking Him to come into your heart and life. You can do that at any time, but it is so important to know him as your savior and follow His word daily — so you too can face your adversity with God in your favor.

You will face battles in your lifetime. Walking in a deeper relationship with God will develop stronger courage. It builds strong faith and patience to wait on Him to lead you to your miracle.

Joshua 1:9 says, “Have not I commanded you? Be strong and courageous. Do not be afraid or dismayed, for the Lord your God is with you wherever you go.”

Don’t forget Him in your busy day. Take Him with you daily.

Don’t wait for your difficult seasons in life to become strong in your faith. Just being in God’s word daily will strengthen you to trust totally in Him for whatever you face. Just read His word. He tells you all over the Bible that He will protect you, and heal you, and help you.

I firmly believe that God placed me at CTCA to strengthen my faith and to anoint me to share my story with others.

I want to thank my sister Shelia and my husband Wally for their unwavering and outstanding caregiving. They helped me heal and stay focused on resting. I want to thank Sonya for giving me the ultimate gift of life, and for God who saved me by dying on the cross. Without Him, we all would be nothing.

I have learned that God did not choose to anoint me with healing to showcase my strength, but to reveal HIS strength.

My message to others is that you can get through a big deep valley. You must mind your thought process and let God handle the rest. He surely has for me.

And at 19 months post-transplant, I am still “Thanking Jesus for my healing”.

---

Believe

Happy Doctor’s Day
March 30, 2019

Eleven months after transplant!
ALL FIGHTING FOR WHAT MATTERS!

JOHN KENISON
Hannibal, Missouri

I spent a couple of years watching my blood counts go up and down and my platelet count decreasing. It was June 2017 when I was diagnosed with MDS by Dr. Ali at the James Carey Cancer Center in Hannibal, MO. We made a trip to MD Anderson Medical Center in Houston, TX for a second opinion. They agreed on the diagnosis, and the treatment. My wife and I discussed the options we had, and I decided one good year was better than 2 or maybe 3 years with the treatment. I discussed this with each of my five children and received mixed reactions. I asked them to prepare the grandchildren in their own way, when they thought the timing was right. My three older boys were ok with my decision. My youngest daughter was upset and called to talk to me. She had cried all week and thought I needed to do whatever was needed even if it was only 2–3 years. My older daughter became very angry and told me in no uncertain terms that I would not let any of them get by with that decision. She also felt I needed to do all I could to fight the disease.

Jeannie, my 4th child, has a 9 year-old son, Chase, who is in karate. He wrote the letter here, and gave it to me. I also received a letter from another grandson who said he was thinking about me and hoped I do not die. With all the objections from my kids and grandkids, I changed my mind and started treatment for MDS in July 2017 in Hannibal, Missouri. My 9 year-old grandson, Chase, has progressed in his karate training, and I have shared in his accomplishments. He had a karate belt made with his name on one side and MDS Awareness on the other side; and a key chain made for me that has the MDS logo. He told me to carry it with me at all times. He told me he was fighting for me and wanted me to fight for him. I know he supports me, and I support him. Together, we have both done quite well, in spite of hurdles that we faced.

I have gotten good reports on my progress. The Dacogen treatments are working well for me so far. I have to take the drip for five consecutive days each month. The week of the treatment, and the next week, I feel very tired and not very energetic. There is also pain in my legs, an upset stomach, and I walk slowly as the platelets and blood counts go down. However, this all improves over the following two weeks, as counts go up and I have some quality time. After a couple treatments, we found I did not need transfusions. I am now able to go an extra week before the next treatment as the counts continue to increase. This gives me an extra week of feeling better before it is time to start over. I continue to go to MD Anderson for check-ups every 6 months. They agree the treatment, and the extra week, is working well for me.

Chase has also progressed very well in his karate. He won 3 national titles at the end of 2017, and has done quite well in many tournaments. Additionally, he was recruited by a travel team out of St. Louis. His photo has been used on several promotional magazine covers — some of which have allowed him a platform to encourage donations to the MDS Foundation. Chase also tried out for the USA team at the age of 10, and qualified to compete in 6 events in Athens, Greece, at the end of October. While in Athens, he heard on the news that it was MDS Awareness Day, and chose to wear a shirt they had made that says “Fight for what Matters” with the MDS ribbon. He wears this quite often. Chase made finalist in all of his weapons and forms events, and came home with Bronze Medals in all of them.

His brother, Jacob (age 5), told me at Christmas that he is going to fight for me as well when he goes to his karate tournaments. He also wears the “Fight for What Matters” shirt.

Dear Grandpa,
I know that you have been sick, and doing treatments, and to help you get better. You have been trying to fight it for a few months now, and I know that you are a fighter, and so am I. You are trying to fight it because, you want to stay alive. You want to stay alive for us, and everyone else you love. I will be competing in NASKA next year, in the black belt division. This year’s fight will be for you. I have a new belt coming with the MDS ribbon on it, just like yours. This will be worn at every tournament I go to. I feel like if we fight together, we will both win. Every time I feel like giving up, I will look at my belt, and that will help me push through it. I hope you can do the same. If you don’t give up, I won’t give up. I love you, we will fight this together!

Chase
The love and support of my whole family has meant so much to me, and has brought me this far. My kids, grandkids, and I can talk about my disease as well as about their shortcomings, disappointments, and accomplishments. We are all fighting very hard to work together to improve and better ourselves in all areas. I have an 80 year-old sister who also calls me after treatments to keep updated on my test results. My wife is the one who is with me at each appointment, keeping the records, and making sure we have the information we need. She encourages me daily. The week of the drip I am not very alert, and she drives me around. The weeks to follow, as I feel the side effects and discomforts, she is there for me. I love her very much and I am thankful to have her help. I was amazed to find this year that I could still get on the dance floor with her. In the picture of us dancing, you can see the MDS keychain my grandson gave to me, hanging out of my pocket.

I would like to encourage everyone to do as my family wanted me to, and give treatment a chance. One of the doctors at the clinic, Dr. Buckstein, told me prior to starting the treatments that even though the success rate of the treatment for a man my age may be low, I may be the one in that percentage — but would not know without trying.

With other health problems as well, I was amazed to find it IS working well for me. I met a woman at my last visit at MD Anderson who told me she has been using this same treatment for 12 years. My wife asked her if she also felt tired and had no energy while taking the treatment. She replied she used to, but as her hemoglobin and other counts went up things improved. I am glad I was encouraged by my family to do the treatments and feel I have made progress. I realize the treatments will continue the rest of my life. I have also been comforted and encouraged in watching and communicating with others dealing with the same disease. For those with MDS, please do not feel defeated and give up. There can be hope and improvements as time goes on.
OUR PATIENT STORIES

WATCH AND WAIT — MDS DOESN’T HOLD ME BACK

BRIAN ANDERSON
Woodbridge, Virginia

Diagnosis

My story begins in November of 2013 after a routine annual check-up with my doctor. I was 49 years young. Overall, my exam was uneventful, but a few days after my examination I received a call from the doctor’s office asking me to return for a second blood draw.

I really wasn’t concerned until my doctor said he couldn’t explain why my counts, particularly for my platelets and white blood cells, were so low. The anxiety began to climb when he referred me to a hematologist/oncologist. Healthy people don’t need to go there, do they?

Search for Answers

During that first trip to the hematologist/oncologist in December of 2013, a bone marrow biopsy was performed and was found to be normal. Unfortunately, it did not shed any additional light on my condition and my doctor was unable to pin down a diagnosis. I went through a battery of tests. I tried a few different local doctors and spent those years receiving generic diagnoses of pancytopenia, thrombocytopenia, neutropenia, anemia and even copper deficiency. The cause for my lowered blood counts eluded my doctors and frustrated me.

Although I was frustrated, I didn’t let my condition slow me down. I still ran 6-8 half marathons and 10K running events per year, joined a kickboxing gym, started biking and generally became more active than before. This wasn’t particularly easy. I was slow and never in contention to win a race, but always had just enough energy to finish. I still didn’t know what was wrong with my blood, but at this point in my life I felt relatively healthy and was in the best shape of my life.

Diagnosis

Fast Forward: In the fall of 2016, my neutrophil counts really started to decline and my hematologist wanted to start me on the steroid prednisone. He was worried that my counts (ANC 0.2 X 10^3) were so low that I was at serious risk of getting potentially life-threatening infections. As much as I was concerned about infections, I was less interested in being on a steroid just to see if it worked. Consequently, my wife and I packed up and flew to Moffitt Cancer Center in Tampa, Florida to get a second opinion.

A few blood tests and another bone marrow biopsy later, my new doctor called with the results and a new diagnosis — de novo, hypocellular myelodysplastic syndrome (MDS). The subtype is refractory anemia with excess blasts, also known as RAEB. He then told me my Revised International Prognostic Scoring System (IPSS-R) risk classification was Intermediate. This risk is associated with the chance of MDS progressing to acute myeloid leukemia (AML).

The hypocellular variant of my disease mimics aspects often associated with another disease affecting bone marrow, aplastic anemia. This similarity is rare but happens in 5–10 % of MDS patients. The difference in my case was the presence of 5% abnormal blast cells in my bone marrow and dysplasia (the abnormal shape and size of my blood cells).

Initial Treatment

My doctor chose to initially treat my MDS using an immunosuppressive therapy of horse anti-thymocyte globulin (h-ATG) as would be done if I had aplastic anemia. He saw a 30% chance that using h-ATG might “reset” my marrow and hopefully see my blood counts return to normal — at least for a while. We thought 30% was good enough and decided to initiate treatment.

In December of 2016, just over one month since diagnosis, I became an inpatient at Moffitt Cancer Center and received the h-ATG treatment. Except for a few incidents of unnerving fever/chills and the necessity for a few platelet infusions, the treatment went well. Fortunately, my wife could stay in the room and was able to sleep on a large chair that converted to a flat bed. Having the support of family is as important to the healing process as the knowledge and skill of my doctors and nurses.

I was discharged with a list of prescriptions that included antibiotics, anti-viral and anti-fungal drugs, steroids and the immunosuppressive drug, cyclosporine. Over time, I tapered off the steroids, followed later by the anti-bacterial, viral and fungal medications. Eventually, the only drug that remained was the cyclosporine. My blood was monitored weekly and adjustments were frequently made to the amount of cyclosporine I needed.

After 5 months, it was clear that the treatment did not have the effect on my bone marrow that we hoped for. My white blood cell and neutrophil counts fell to levels that I had before the h-ATG was administered. Additionally, my anemia worsened. As my hemoglobin dropped, so did my energy. Before the treatment I had completed some challenging half marathons, I now found myself getting winded walking up one flight of stairs.

In May of 2017, I had a conversation with my doctor — it was clear the treatment was ineffective and we decided that I should stop taking the cyclosporine.

Watch and Wait

As many struggling with this disease know, “watch and wait” is the treatment plan for many low to intermediate risk patients. I am now in that watch and wait category.
What does watch and wait mean for me? Right now, it calls for semi-annual trips to Moffitt to see my doctor and bi-monthly blood draws for routine CBC w/diff and a metabolic panel. No medications, over-the-counter or otherwise are required, and azacitidine (Vidaza®) is not yet needed. There aren’t any currently recruiting clinical trials that apply to my situation.

My Moffitt transplant doctor agrees with my current treatment plan. Although he and his expert transplantation team stand ready to perform an allogeneic stem cell transplant, the only known treatment to cure MDS, he does not think now is the right time. He worries that despite my excellent health and the advantage of my relatively young age, the risks associated with stem cell transplantation outweigh the benefits. The game now is to simply monitor my consistently substandard blood test results and live my life.

Life Moves Ahead

My watch and wait status let me continue to do things like participate in MDS Walks in Boston and 5K March for Marrow runs in Washington DC. It lets me continue to work, travel and more fully participate in the lives of my family.

But watch and wait is frustrating because I’d like this to be... done. I’d prefer not to be anemic and have more energy. I’d like to not worry about excessive bleeding or bruising. I also don’t want to worry about contracting a potentially deadly virus, fungus or bacteria whenever I leave my home as even shaking hands with a friend can have devastating consequences.

In time I know that a stem cell transplant might cure my MDS and return my life to a relative normality but it can potentially introduce new equally life-threatening medical issues, like graft versus host disease where my donor transplant’s immune cells attack my own organs and tissues.

I also decided to get another opinion from the team at Dana Farber Cancer Institute in Boston, MA. There, my doctor did even more genetic testing and looked at the length of my chromosomes for something called short telomeres. Having shorter telomeres at the end of chromosomes is not a good thing from a prognosis perspective. After the tests came back, I was fortunate to discover that my telomer length was normal. With no additional discovery of genetic or chromosomal abnormalities, I was returned to my Watch and Wait status.

Deciding to take more control of my future, I decided to start up a support group for patients with MDS in the Washington DC area. It has been a wonderful experience to both share my story and listen to those of the participants. I also journal my thoughts to keep my mind focused and sharp. I have learned to lean on the support of family and friends and do so without reservation or hesitation. This is too big for one person to handle alone.

For now, learning to live with the uncertainty that things can get worse at any time is hard, but with the proper support from family and medical professionals, it can be done. I keep a cautious eye on my labs, continue to work with my support group and keep a positive attitude. Before I learned of the significant risks, a transplant was what I wanted. Now, I simply hope to live as long as I can in this watch and wait state with a good quality of life before a transplant becomes necessary. It’s the best plan that I could have and I’m happy to have it!
OUR FAMILY’S JOURNEY, TOGETHER

CHRIS BARrett
Worcester, Massachusetts

On a warm October afternoon, my cell phone rang displaying a call from the hematologist at UMass Medical Center who had been treating our 16-year-old son, Matthew, for six months. I put it on speaker so my wife Marybeth and I could both hear. “The last of the tests came back,” Dr. Newburger said. “Matthew has Myelodysplastic Syndromes.” The details that followed are vague now, but he explained that Matthew’s bone marrow was failing to produce healthy blood cells and that given Matt’s condition he would need a bone marrow transplant. He emphasized that if the bone marrow transplant were successful it would be a cure, and told us that he was referring us to Boston Children’s and Dana-Farber. Our minds were swimming.

Six months earlier, Matt was admitted to UMass with high fevers and such low blood numbers that doctors thought he might have leukemia. However, his bone marrow biopsy revealed no leukemia. His fevers persisted for thirty-six days, waking each night in drenched sheets. He lost weight, was fatigued, and missed much of the final quarter of his sophomore year. But by June Matt was slowly improving. His blood numbers were modestly better, and he had the endurance to return to school part-time. Marybeth and I felt the worst was behind us. Occasionally, his doctor would call letting us know that he was still pursuing Matthew’s mysterious illness and troubling lab results, and consulting with doctors in Boston, Philadelphia, at the NIH, and in Cincinnati. I appreciated his diligence, but privately felt it seemed superfluous since Matt was looking so much better. How wrong I would be.

At the end of August, the day before Matt was to start his junior year, Matthew and Marybeth arrived at Dr. Newburger’s office for follow-up lab work. A half hour later the tests showed Matt’s numbers were alarmingly low. The results were so unexpected given that Matt was feeling better, that Marybeth asked him if he was certain that he was looking at that day’s labs, and not the April reports when Matt was sick. He assured her that he was. Another bone marrow biopsy was ordered, as well as DNA testing. Seven weeks later, Dr. Newburger called us on an October afternoon with the results. “It’s a very rare condition,” he said, “only recently described in the last few years in the medical community.” “How rare?” we asked. “Less than sixty cases.” We sat quietly digesting the news. We hung up the phone wondering how we were going to tell Matt and his older brother Dan, and his two older sisters, Kate and Sarah. Later we would come to feel deep gratitude for Dr. Newburger’s quiet dogged pursuit to get to the bottom of Matt’s poor blood numbers.

At the end of October, during our initial meeting, we met with MDS specialist Dr. Inga Hofmann of Boston Children’s Dana-Farber. The bone marrow transplant, she told us, would be scheduled for the beginning of December, and Matt would be admitted to Boston Children’s. It was at this first day of meetings that we and Matthew got to fully hear his diagnosis, the treatment plan, the challenges of going through a bone marrow transplant, but also the promise. It was a lot to take in. Marybeth and I wondered how all this sounded to him. We’d intuitively look at him as the doctors talked to see if we could detect his reaction. On the drive home, Marybeth asked him, “So what do you think about everything you heard today, Matt?” He paused and said from the back seat, “I won’t be needing a haircut for awhile.” Matt’s sense of humor would be consistent throughout the experience. For the next year he’d joke with us, his nurses and CNAs, post comical pictures of his hospital room and his balding head. He found continual humor joking about his bodily fluids. His sisters rolled their eyes. His sense of humor would help him, and us, through the demanding physical struggles and complications he endured, and the emotional strain it put on all of us.

We felt reassured that we were in the most capable of hands. But still, there were the questions, the uncertainty, the risks, the what-ifs. We had many late night conversations. Matt’s health and the approaching BMT pre-occupied our thoughts day and night. We worked hard at keeping a sense of a normal routine and of being attentive to our other children – but underlying all of this was deep concern. Many nights I’d hear Marybeth awake at 3:00 AM tossing and turning. At times there were no words that would ease the stress, so pulling her close seemed to slowly calm both of us. We prayed a lot. We prayed for healing and a successful transplant, we prayed for wise doctors, we prayed for good parents, and we prayed for God’s presence – to not leave us alone, to always be with us, to help our family grow closer because of this. We vowed not to let the beauty of each day be swallowed by the legitimate concerns we had. We would remain grateful and find the daily blessings given to us.

During our second visit to Dana-Farber, we coincidentally received a phone call from Dr. Newburger who told us that both Sarah and Kate were perfect bone marrow matches for Matt. Relief! Matt called Sarah on the way home. I could hear her scream of joy from Matt’s cell phone. Sarah was the one closest in age to Matt – only a year and a half older, and the two played together growing up. Sarah mothered him, soothing him with attention when he was an infant and toddler and dressing him up in whatever costume she thought appropriate.

TOGETHER, OUR FAMILY’S JOURNEY, TOGETHER
for the imaginary game she was playing that day. It seemed remarkable that nestled in Sarah’s bones, like a gift she had been quietly nurturing for eighteen years, was the cure for Matt’s MDS.

Thanksgiving was nearly the height of our pre-BMT stress. Traditionally we head to New York to visit for a few days with Marybeth’s family. We both come from large families. Our children have 43 first cousins! Our Thanksgiving visit would be the last time Matt could see everyone for months, so of course we wanted to be there. But with the bone marrow transplant only two weeks away, we worried how to keep him healthy around so many cousins. Any sign of illness and Matt’s BMT would be pushed back until he was healthy and a bed became available – perhaps months away. The visit was marvelous for him, but by the time we left, the worry felt like a weight in my head. One look at Marybeth told me she felt the same way. Thanksgiving was over. We were now in countdown to his admission date.

Arrival at Boston Children’s 6 West strangely felt like a relief. We were here. The pre-conditioning done, the wait over, the logistics largely worked out. I took a leave of absence from my middle school teaching job. A generous friend arranged for a hotel room nearby. I would sleep on the cot in Matt’s room. Marybeth would catch a few hours of sleep every night at the hotel. Sarah, who was a freshman in college, would come to Boston Children’s to donate her bone marrow on December 10th, just after classes were done and before exams began. We were amazed at her poise.

We hung a world map on the wall. In our earlier meetings at Dana-Farber we were struck by how many doctors, nurses, and staff were from around the world. It felt to us as if the world was coming together to save Matt. We wrote each name of every person who attended to Matt next to the country they were from. Doctors, nurses, custodial staff, recreation therapists, and nurse assistants from Germany, Russia, Italy, England, Canada, Nigeria, Pakistan, the Dominican Republic, and the United States. The map became a bit of a celebrity in its own right. By the end nearly 50 names dotted the map. Two and a half years later, when Matthew went off to college, he would hang the map in his college dorm room.

Over the next few days mail arrived from his cousins – letters of encouragement and posters with photos of all of them swimming at the lake, celebrating holidays, and on family outings. They were immediately hung on the walls of his room. The chemotherapy was fatiguing him. He slept more and his appetite dwindled. By the afternoon of his fourth day of treatment doctors were concerned with the electrolyte imbalance in his system. He slept around the clock. Doctors were concerned. They explained that they would try another course of action to improve the saline concentration in his system, that he would be closely monitored, and at his next lab draw at 2:00 AM, they were hoping to see an improvement. If not, Matt would need to be transferred to ICU. Marybeth stayed that night. We fitfully fell asleep around midnight. At just after 2:00 AM the attending doctor gently touched my shoulder to wake me. When I saw him leaning over me my stomach sank. “This can’t be good,” I said. “Matt needs to go to ICU,” he told us. “They are waiting for him.” Marybeth leaned over Matt’s bed and hugged him and quietly cried. As I left to talk to the doctor in the hallway, I heard Matt whisper, “It’s going to be okay, mom.”

The first few hours in ICU were nerve-wracking. Doctors increased the concentration of saline to help get his body back in balance. Our nurse, who must have seen the worry on our faces, was reassuring. The chemotherapy, which was to destroy his ill bone marrow, was now wreaking havoc on his whole body. At early morning rounds, the ICU team and the bone marrow team gathered outside his door. A young ICU attending physician was clearly in charge. She explained the protocol, told the results she expected to see, and exuded such a confidence that we started to feel a small amount of relief. The BMT team then explained that the next chemo dose would be administered here in ICU later that day. At the end of the conference, I turned to the attending BMT doctor and asked, “So if the ICU doctors have a hard time getting his system back in balance can we stop the chemotherapy for a few days?” She looked somberly at me and shook her head. “No, we can only keep going now.”

Matthew responded well to the increased concentration of saline. He became more alert and interacted with us. Matt remained in ICU for the remaining four days of his chemotherapy treatments. He returned to the BMT floor ready for his transplant.

Sarah arrived in Boston the night before and stayed over at the hotel with Marybeth. In the morning, she was
wheeled into the procedure room to have her healthy bone marrow aspirated. Matt waited in his room for the miracle to arrive. Remarkably, the nurses were able to reserve the room right next to Matthew’s for Sarah’s recovery that afternoon. While Sarah slept off the effects of the anesthesia, the lab technician prepared her bone marrow to be dripped into Matthew later that evening. At just after midnight on December 11th, Matt’s nurse carried Sarah’s bone marrow into his room. It looked just like a regular bag of blood, but in it were the stem cells that would come to repopulate Matthew’s now nearly eliminated bone marrow, and create a whole new healthy blood system for him. Matthew lay in bed sleepy from the Benadryl dose he had taken earlier to prepare for the transplant. The nurse asked Sarah, who was sitting in a wheelchair in a hospital johnny next to Matt’s bed, if she would like to turn on the drip. She gladly reached over and pushed the button. Her bone marrow slowly dripped into the port in Matt’s chest. We cheered. Matthew raised one arm high in the air eyes still closed. Sarah reached out and gently rubbed his head. It was the beginning of a new life.

Remarkably, the nurses were able to settle into a routine at home. My day was focused on Matt. Waited each day for the news of his blood counts and although he would be readmitted one week for his follow-up appointments. With no school schedule to keep his sleep regulated he started staying up late playing on-line video games with a group of guys who would become his on-line friends during his isolation. We cooked him any food he wanted trying to entice him to eat. When he left the hospital he was but 119 lbs. on a 6’ 1” frame. Through the months he would deal with nausea, loss of appetite, dry mouth and red, dry eyes. Doctors monitored for GVHD. He battled some opportunistic infections — the worst being a urinary tract infection that was quite painful. Later at his one-year check-up, his doctor would tell him his transplant looked great, but also acknowledged, “You endured your fair share of complications, Matt.”

Social media seemed to be blessing and curse. It was a way for Matt to stay in touch with the outside world, but it also was the place to view the curated lives of his peers and remind him of what he was missing. Winter gave way to spring and then summer and Matt could get out more in the fresh air and see friends in our backyard. Doctors gave him clearance to return to school in September, nine months after his transplant. Matt returned to school as a junior — having missed nearly all of his junior year. His first few days were joy for him. He was out of the house. He could be with his classmates. “I just looked out the window of class at the trees,” he told us one evening with appreciation in his voice. Yes, there were still some precautions, but generally he was to be treated like a normal high school boy we were told.

Except that things weren’t all that normal. He was still drained and easily tired. He found focusing in class nearly impossible. He called it chemo fog. We suspected that he might also have ADD, which would take another two years to have properly diagnosed. He went to school late on many mornings or would need to come home early. He was in effect a part-time student for most of his junior year. But worse, underneith the physical effects and unbeknownst to us, was all of the mental wear and tear he had endured in isolation and the effort at trying to re-integrate to school. People treated him like
everything was great now, or did not even acknowledge what had happened, but Matt was changed and he felt that his peers could not see nor understood what he had been through. He had been forced to journey to another land – one of mortality, doctors, uncertainty, stress, fear, and complications. It was a part of him now but he seemed alone in it. A piece of artwork he made later that spring captured his emotional and mental isolation – it is of two silhouetted figures. The one on the left is labeled “Cancer”; the one on the right “PTSD”. Over the cancer figure are the icons found on social media “likes,” “comments,” and “shares.” The cancer figure has hundreds of likes, comments, and shares. The PTSD figure has zero next to each icon.

Now more than one year after his transplant we noticed he seemed angry and belligerent often. He was struggling desperately to connect with his peers and to find friends. He confessed he was eating lunch alone in the bathroom at school. One night he sat on the landing of our staircase head bowed between his bent knees sobbing that he did not have any friends. As hard as the transplant was, this seemed even harder — to watch a seventeen year old son sob as Marybeth wrapped her arms around him. It was almost too much to bear. He saw us as often suffocating him and could be very explosive toward us. We were deeply concerned, but figured with our love and support he would get through it. What we should have seen was that he was presenting symptoms of depression and anxiety. It was only after he was up late one night, which continued to be his pattern even after he returned to school much to our chagrin, that he told us he had been trying to get in touch with the psychologist at Boston Children’s he occasionally saw when he was an in-patient. He was crying for help, but we missed it. We hugged him and told him that we would call her immediately. She told us to bring him in that afternoon. I felt that I was coming up short. My entire focus was on Matt and his well-being for a year and a half, and yet while his physical health was improving, his mental health was deteriorating. And I failed to see it.

For the next couple of months we would drive into Boston once a week to see his psychologist. He enjoyed talking with her. She gave him strategies to deal with his depression. He was more open in talking with us. We discovered a teen group at the Jimmy Fund clinic and he immediately joined. They would help open up a path of healing. Over the next year Matt went on many outings with the group, including a spring training trip to Florida to see the Boston Red Sox. He loved the other teenagers. “We all get each other,” he said after one trip.

In retrospect, I now wish that part of Matt’s regular check-ups at the Jimmy Fund included a check-in with a counselor. Mental health counseling was readily available when he was an in-patient, but not as an outpatient. So much of our time and the medical professionals time was spent on Matt’s physical health, and indeed, it needed to be. But I realize now how beneficial, indeed essential, it would be if equal attention were paid to his mental health post-transplant. The toll of such prolonged isolation and the challenge of re-integration, I have come to realize, is an enormous struggle, especially for teenagers. Of course, this will require additional human resources, and perhaps changes to insurance companies’ coverage. But from our experience, if we truly want to give comprehensive care to those people who have been through such trauma, especially children and young adults, then attention to mental health must be equal to physical health.

It would still take many months for Matt to negotiate his relationships and the world post-transplant. A chance meeting with a childhood friend he had not seen in years in a local frozen yogurt shop became the unexpected bridge to a group of high school kids who finally accepted him. Another miracle, we thought. I think he is still working out his new post-transplant reality. He is hypervigilant about his health. When he came down with pneumonia this past February while away at college, he feared he was actually suffering from a serious condition he once heard his doctor mention at one of his check-ups a year earlier. Marybeth had to reassure him at midnight that it was not that. He spent the better part of February at home recuperating.

Matt is now three and a half years post-transplant. Doctors are exceptionally pleased at the transplant. His good health is a testament to its success. We all feel grateful for how well he has done and the new life that his transplant has given him. Yes, I still look for signs of any trouble in his mental health. I think that will last for awhile. And there are mornings Marybeth and I awake and feel slightly unnerved. We can read it in each other without having to say anything. We have endured the unexpected hardship that life can hand out. It has left its mark on us too. But when we are able to step back and see the whole picture, we feel immense gratitude for the doctors, nurses, psychologists, his siblings, our daughter-in-law, and our large extended families who walked with us every step of the way.

Last week we were at the lake in Vermont at a small house my in-laws have. Marybeth and I were up early sitting in Adirondack chairs looking out at the still lake. The sun was just up and the air had a morning coolness to it. Matt sat in an old canoe fishing only twenty feet from the shore. His siblings were still asleep. He cast his line and slowly reeled it back in. He looked liked the little boy who had done this so many summers before his illness. But here he was, twenty years old now, having endured his transplant and the many challenges. He was healthy. As I watched him, a wave of gratitude washed over me. I reached over to touch Marybeth’s hand and I softly cried.
IN LOVING MEMORY...

GREGG OSHITA
Cincinnati, Ohio

Unlike other stories you have read in the newsletter, our story is written in loving memory of Robyn Anne Oshita who passed away in October 2017 after losing her valiant battle with a rare form of AML where she required HLA transfusions twice a week, after it converted from MDS. Prior to her diagnosis, Robyn had been healthy all her life. It is our hope that by telling our story, it will help other families avoid the pain and sorrow our family experienced.

Robyn graduated from University of Illinois nursing school in 1974 and we were married the following year. Over the course of the next 42 years of our marriage, we were blessed with 2 beautiful children, Michael and Kimberly who grew up loving, kind and responsible adults. Nursing was the perfect career for Robyn because she befriended everyone she met which allowed her to quickly gain the trust of patients she treated.

Robyn retired in October 2016 and we were looking forward to traveling and spending more time with our kids. Life was good and the world was our oyster... or so we thought.

In July 2017, Robyn was experiencing shortness of breath and bruised easily. A blood test revealed Robyn’s platelet count was extremely low, 10,000 versus a range of 150,000–450,000 in a healthy person. As a result, Robyn required a minimum of 2 matching platelet transfusions a week to prevent her from hemorrhaging. Since Robyn required special type of platelets (HLA), which were rare, our family stressed and worried, daily, for 2 1/2 months if matching HLA platelets would be available when Robyn needed them.

Two weeks later, in August 2017, Robyn was diagnosed after a bone marrow biopsy with Myelodysplastic Syndromes (MDS). Although her prognosis was not good, we were hopeful because her number of blasts was less than 5%. Her doctors told us that Robyn needed a bone marrow transplant within 7 months, before her MDS converted to AML, to survive. Luckily we were able to find 2 matching donors over the next month who said they would donate. Unfortunately, Robyn’s MDS converted to a rare form of Acute Myeloid Leukemia (AML) in 2 months versus the projected 7 months, and Robyn passed away in October 2017, 2 1/2 months after her initial diagnosis.

Robyn’s closest childhood friend said this at her memorial service last year... “In reflecting on all our shared childhood and adult experiences, the words that surface are compassionate, kind, giving... but most of all humble. Robyn always stepped away from the limelight; she was really good at deflecting attention from her accomplishments to others. Robyn you will see from your perch above how deeply you have touched our lives and left a loving legacy.”

Our family never expected to lose Robyn at such a young age especially since she was healthy all of her life prior to her diagnosis in July 2017. My children and I created a nonprofit 501(c)(3) foundation in loving memory of her called The Gregg and Robyn Oshita (GRO) Foundation (www.thegrofoundation.org) in January 2018. Our foundations mission is to inspire individuals to donate blood, plasma or platelets and register for the National Bone Marrow Registry, “BE THE MATCH” to help save the lives of loved ones battling serious illnesses. Whether it is the 2-year-old girl battling leukemia in Georgia or the new mother in Chicago battling cancer, please join us in helping save the lives of loved ones battling serious illnesses by donating at your local blood center. Although an estimated 38 percent of the U.S. population is eligible to donate blood at any given time, less than 10 percent of that eligible population actually donates blood each year. According to “Be the Match”, a national bone marrow registry, even with a registry of millions, many patients who need donors who are a genetic match cannot find one.

The link below is another example of why our foundation exists. Thanks to people who donated to our foundation, we donated to Phoenix’s GoFundMe page. Surprise daddy-daughter dance goes viral. https://www.cnn.com/videos/health/2018/08/21/daddy-daughter-dance-hospital-prince-charming-orig.cnn

Please join us in giving the most precious gift of all...the gift of life.
The MDS Foundation relies on gifts to further its work. We would like to acknowledge the generosity of the following individuals and organizations that have recently provided gifts to the Foundation:

Abigail Abonga • Sharon Adair • Marcelle M. Adams • Quintin and Nadine Adamski • Joanne Adleberg • Administrative Council of Oneonta City School District • Rich Ahearn • AIA Palm Beach • William Ainsworth • Donald Allen • John and Alice Allen • Bernard Alter • Renee Ambrosio-Alexander • Brian Scott Anderson • Donna Anderson • Gerald and Joyce Anderson • Frances R. Applebaum • Alejandro Arenario • Ron Arissio • Kathleen Armstrong • John and Sandy Arnett • Heather Aspegren • Atlantic Land Management, Inc. • Audrey Grant • Complete Property Mgt • Paul Avongnassou • Mary Awad • Russell and Arlene Baccaglini • Craig and Connie Bailey • Stacey Bainee • Richard and Susan Baldwin • Kelly Babka • Cara Bardwell • Bar None Cowboy Church • Elizabeth Barnhart • Adrienne Donofrio and Jamie Barone • Alexander Barr • Tom and Linda Barry • Barbara, Al and Joshua Barza • Michael Beausir • Steven Bechtel • Anita and Murray Becker & Family • Catherine Behrend • Esther Beile • Susan Benjamin • Dr. John M. Bennett • Dave and Penny Bergerson • Marvin Berlin • Larry and Randie Berman • Jen Bernstein • Joan Bersofsky • Tom Bertell • Steven Bessel • Susan Billy • David Blivaiss • Ralph Blumenstock • Patricia Bonelli • Edward Bonham • Dana Bonner • Alise Borachok • Alex Bourdelais • Carol Bowerman • John Boyce • Zay and Cinnamon Bradley • Larry and Alice Brauer • Phyllis and Bruce Brenner • Mary Bressette • Broome County Department of Social Services • Kathleen Brown • Sue Brown • Meredith R. Bruce • Donna, Dave and Davy Bunton • Nate and Liz Buono • Cherly Burden • Daniel Burger • Kenneth and Helene Burgess • Richard and Ann Burg • Carol Burns • Robert and Ellen Busch • Doris Faye Byer • Catherine Cahill • Natalie Cahill • Anne Cahn • Joseph Cantore • Jeanne Cardenas • Roslyn Carney • James and Janice Cassin • Tena Chacko • Gabriel Chan • C.H.D. Class of 1963 • Randolph and Elizabeth Chinney • Linda Church • Alicia Ciranni • Citizen National Bank • Nancy Clayton • Devon and Gary Clement • Sharon and Nathan Cohen • Jennifer Cole • Comcast Corporation • Jane Connelly • Kenneth Connney • Renee Conrad • Jane Corr • Joseph Costa • Andrew Coulter, Jr. • Michael L. Craig • Jeffery Kahn and Genie Craft • Lisa Crowley • Dixie L. Crump • Neil and Ruth Cuadra • Al and Marcia Curtis • Raymond P. Daniels • Douglas and Marilyn Dantuono • DeAnna Darling • Anastasia and Thomas Darratt • Davison County Commission and Employees • Linda Day • Mark and Martha De Noble • Deb, Vicki Langenhuizen, Matuszak • Ken and Tracey DeFurio • Roberto Degl' Innocenti • David Dehring • Clifford and Alice Deitrich • John and Joyce De Jong • Barbara Delcamp • Shane DeSimone • Joseph DeSimone • Jack Deutsch • Rosemaria DiBenedetto • Lon and Barbara Dienst • Jack and Sandra Dilbeck • Dennis D. Dillon • Rogers and Kathy Dixon • Thomas Dollinger • James Donnan • Ted Dorf • Richard L. Doughty, PhD • Melissa Drahalal • Timothy Dunne • Russell and Marie Durveya • William and Nina Dziepak • Victoria Connor Eagen • Henry Earl • Allen and Elaine Edmister • Christopher Elliott • Jean Ellis • Doris Emmons • ENSCO HR Team • Suncor Energy • Melissa Engle • William and Linda Enzweiler • Mary Epstein • Marilyn Ernest • Bill Evans • Barbara Falkingham • Family of Williams-Palmo-Claucus • Jane Felder • Harvey Fendelman • David and Shirley Fenner • William E Ferguson • Raymond Ferraro • Christopher Festa • Andrew O. Feuerstein • Marianne Ficarra • First Baptist Church • Dave Fisher • Thomas Fisher, III • Wayne Fleischhacker • Barbara Flynn • Linda Ford • John Foster • Patricia J. Fox • Elizabeth Frey • Robert and Sara Frey • John and Beth Frey • Lee and Julian Friedman • Jeremy Friese • William N Fry • Nancy Gabriel • Elise Sue Gad • Bobby and Zvi Galani • Kathleen Gallant • Sheila and Alan Gallanty • George and Ellfriede Galuschak • Heidi Garber • Dennis and Vicki Gardner • Pam Gardner • Suzanne Gaskill • Betty Lou Gaudiano • Susan Del Gaudio • Margaret Gavis • John Gibson • Andrew Paul Glasgow • Marissa, Craig, and Benjamin Dixson • Thomas Glazewski • Glen Arden Community Assn • Bill and Barbara Glodfety • Catherine Goll • Hannah Goldberg • Will and Pat Goldschmidt • Walter Golembiowski • Lewis and Sylvia Gollub • Bob and Rhonda Gonsavles • Ann & Steve Gordon • Dr. Steven D. Gore • Howard Gorney • Gosting & Company, P.C. • Froehling Anderson LTD • Ilza Gottlieb • Paul Goucher • Grande Oaks Golf Club Family • Great Plains Staff • Jonathan Green • Peter L. Greenberg • Thomas Greene • Harrison Greenfield • Eugene Gregory • John Greve • Marc Gross • Diane Gruber • Harsh Gupta • Shelly Helm Guzek • Jeff and Elizabeth Halvorsen • Ralph and Salome Hamaker • Paul Hammes • Christopher Hamp • Mary and Werner Hampl • Mary Patrice Webster Hancock • Peter and Renee Hanna • Donna Hanson • Ronald Hare • Lisa Harris • Theron and Brooke Hatch • Kate and Greg Hatcher • Judy Ann Hathhorn • Don Hayden • John Hayes • Barbara Pariente and Fred Hazouri • Susan Lee Heinze • Cynthia Heller • Aiola Heller • Heidi Helmiuch • Christine Miller Hendrix • Arnold J. Henig • Robert Hennessy • Nina Jaye Henry • Heritage Seventh-Day Adventist Church • Suzanne Hermas • Kay Herrmann • Marianne Hewett • Jessica and Van Hildreth • Tracy Hill • Diane Hinojosa • Wendy Hinojosa • Paul Hisrich • Brent Hladky • Gail Hoffman • Fae L. Hoffman • Matthew Hoffman • Daniel Hoffman • Daniel C. Hogue • Carol Holman • Anna Holness • Melinda Hopper • Charlene Hrivnak • Roman and Karen Hryciyiak • Antoinette Huber • Gwen Hulbert • Kathleen Hunt • Aaron Hunter • Sandra Hynes • Betsyler • Lois Jacob • Barry Jacobs • Barry and Debbie Jacobs • Frederick Jaffke • John and Deanna Jennings • Tony Jensen • Leonard A. Jewler • Joan and Eugene Johnson • Jane Johnston • Cecile Jolin • Gregg Joly • F J Jones • Tom Jourden • Alvin A. Kabot • Tapan Kadia • Lisa Kalisperis • Penelope Kalogeropoulos • Natalia Kamberos • Jeffrey Kane • David Karam • Gary and Pat Kaufman • Gabrielle Kellerer • Connie Kelley • Lea Kelly • Robert and Andrea Kerlan • Robert and Janice Kern • David Kernahan • Joseph Kesner • Eric Kilichowski • Alexis Kimber • Michelle King • Jean-Ellen King • Trish King • Chester Kirk • Ronni Kirsch • Jenifer Kittland • Richard Klein • Karen L. Kloeppping • Jennifer Knittel • Linda and Gene Koalkin • Jeff Kohnhaas • Mary Pat Kollitz • John and Ruth Kopec • Ken Kossken • Claudia Manta Kotowicz • Cheryl Krauss • Ed Krivak • Dennis Kroeger • Lynne Krumen • Bill and June Kruse • Sheila Kulia • Gary and Susan Kulis • Sonia Kumar • Kathleen Kumm and Family • Bill and Sue Kurtz • Pat Kurz • Robert and Andrea Kurzkon • Marlene Kuskowski • Marko Kuzmanovic • Savanna Lanza • Jeanette Largue • Gregory Larson • George Latsko • Susan Laufer • Kevin Lawlor • Ken and Sue Leasure •
Cara Lee • Sandra Lee • Betty Eng Lee • Linda Leicht • Audrey Lengel Ray Leppik • Charles and Ellen Levine • Joel Levy • Doug and Diana Lewis • Wesley Lewis • Stephen C. Limone • Susan Barber Lindquist • Irwin List • Thomas Logan • Nicholas Lordi • Ashley Lorenzo • Laura Loughney • Mary Anne and Ashley Louis • Omar & Cheryl Lozano • Patricia R. MacCallum • George F. Mackey, Esq. • David and Sandra Madsen • Carly Maietta • David Mandell • Linda Marie • Marine Spill Response Corp • Peter Mariniello • Mark Gary Flying Service Inc. • Richard Marks • Susan Martin • Rosemary Massario • Daniel and Barbara Matheny • Edward Mazria • Leonard McAdams • Kelli McCarthy • Lisa McCormack • Debbie McDermid • Barbara McDermott • James McDevitt • Thomas and Mildred McDonald • Carolyn McGee • Brenda McGeown • Madalyn McGovern • Mary L. McGrath • Julia McGuire • Sheila Swanson McIntyre • Sharel McVey • Dennis and Debbie Meals • Elsa Mederos • Renae Mehan • Abigail Meisterman • Patricia Meling • Gerry Meyer • James Meyers • Marvin Michelman • Maria Midkiff • Chris and Beverly Miles • John Millar • Betty Jane Minncemoyer • Eugene and Judith Mirrer • Leslie Mishner • Scott Mitek • Richard and Sharon Mizialko • Kevin Moore • David Moreira • Jennifer Moretti • Ryan Morgan • Cindy Moriarty • Timothy P. Morris • John and Gail Morrison • Judy Moravy • Jospeh and Sandra Motzkin • Carl and Christy Moxley • Pamela Mroczkowski • Matthew Mucci • Stephen and Rhea Mucha • Sy and Cheryl Mullman • Michael Murphy • Joseph B. Murray • NAI Summit • Jean Naman • Susan Nelson • Karen Newbury • Paula Newcomb • Douglas and Archanza Newcom • Mary Niederle • Dr. Stephen D. Nimer • Freda, Jason, Kerri, Phillip, Tiffany Norman and Family • John M Nosko • Martha Turer Novak • Pat O'Brien • Susan O'Connell • James J. O'Donnell, III • Molly Oechelhein • James O'Garman • Dianna O'Hara • Michael and Kathleen O'Leary • Charles and Vera Orr • Elizabeth Osborne • Rochelle Ostrow-Weinberg • Adriana O'toole • Mary Ottone • Kaileil Padgett • Randy and Judy Paige • Thomas and Diane Panepinto • Frank Y. Parce • Judy Parker • Rita L. Paul • Jill Pavlus • Deborah J. Peirce • Jeffrey Peloquin • Lorenzo and Joan Sharon Pelosi • Bradley Penwell • Richard and Gayle Pervos • William Pesek • Jarred Peterson • Renee Petteruti • PFC Opinion Research • Dawn Phlipower • Merle Phillips • Hank and Bonnie Pikkel • Helen Plitian • Julie Platanias • Pledgeling Foundation • Diane Plitz • Lynn Podoll • Linda Bob Bobbilynn Polands • Carol Polin • Carolyn L. Porco • John Porro • Jessica Post • Earl and Juli Posto • Lori Potter • Rich and Joan Powell • Katie Presley • Karen Priore • Bob and Emily Pritchard • Gerri Propersi • Annette Puczowski • Millie Pyoralu • Robert Quane • Ken and Lori Quann • Shawn Quill • Stephen and Kara Rabinowitz • Shilpa Ramaswamy • Samuel Ramsey • Clement and Joan Rancourt • David Rascher • Larry Rea • Loretta A. Reiner • Louis Resnik • Terrel Reubert • Alan Richer • Kerri L. Riedel • Gina Riela • Ferdy and Phyllis Rivera • Katrina Roaold • David and Mary Ann Roberge • Renee Roberts • Wanota Rodgers • Thomas A Roell • Leroy E. Rogalslad • Ricky Rosado • Jessica Ross • Rita and Donn Rosselet • Karen Roth • Edwin and Beverly Rozendal • Ron Ruderman • Brittany Ryan • Kelly Ryan • Joe and Lois Ryczkowski • Monique Della Santina • S&C Electric Company • Charles Scainef • J. Thomas Williams, Jr. and Nancy R. Schauer • Rebecca Scheier • Lariann Schenking • CJ Schiltd • Dennis and Greta Schnathorst • Claudia Schoenig-Diesing • Mary Ann Schroeder • Markus Schuetz • Stephen and Patricia Schuetz • Joanne Schuchap • Jane and Eric Schwartz • Elaine Schwartz • George and JoAnn Scimanico • Stephen Scota • Erica and Jean Scopiniich • Ronnee Segal • Marcia Seifert • Emmet Seifert • Patricia Seyller • Richard Sgarzi • Shaler Township • Ann Sharon • Tom and Joann Shelly • Sandy and Jeff Shawmaker • Dan Shoman • Eddy and Ginger Shorter • Tim Shuey • Tim and Linda Shuffett • Jean Shumard • John Shutta • Judy Siegfried • Steven Siehr • Nancy Silverman • Chaitanya Singh • Russell and Linda Skaggs • Diane J. Skelton • Barry S. Skine • Joe and Char Skorjancic • Claire-Eliabeth Sloan • Wayne and Irene Smalley • Linda Smith • Renate Smith • David and Carol Smith • Garland Smith • Dean and Karen Smith • Terrilynn Smith • Margaret Snyder • Thomas Snyder • Ronald Solberg • Suzanne Solysiak • Maxine Sortino • Andrew Sortino • Southern Development Services, Inc. • Pam Sparkman • Jon Spivey • Cynthia Stachiw • Janet Stahl • William Stanbach • Beverly Starr • Cindy Starzyk • Barbara Staudenmaier • Mark and Laura Starwaz • Robert Steenso • Paul and Lisa Stepanovic • Howard Stephenson • Joyce Sterlin • Eddi Stockert • Bill Staffol • Elizabeth Stohner • William and Sharon Stone • John Stout • Jeffrey Strelitz • Therese Stuckmann • Randall and Martha Sullivan • Michael Sundquist • Nancy Sundstrom • Lisa Sutner • Sharon Swanson • Douglas Swan • George and Rosemary Swanwark • Mark and Iris Swartz • Gloria Szanto • Doreen Taras • Diane Taylor • Ann C. Taylor • Robert and Patricia Terlizzi • Margaret Teske • The Henry and Marilyn Taub Foundation • The Howard E Nyhart Company • The Lester & Grace Maslow Foundation • The Pells Family • The Robison Family • The Tom and Nancy Bruch Fund of InFaith Community Foundation • The Wolterstorf Family • Virginia D. Thomas • Sandra and Tom Thomas • Chris Thompson • Pat Thompson • David Timke • Theresa Tintor • Joseph and Mary Tomasello • Timothy and Amy Turlington • David Turner • Larry Twymann • Ultimate Software Group, Inc. • David Usher • Keke Uzokwe • Lionel J. Vaillancourt • Rosaria Valenzano • Marcia Vanderlee • Helen Vansikver • Veranda 2 at Southern Links • Verdex Construction LLC • Thomas Vincent • Marcie Vinson • Allison Vitsky • John F. Voit • Donlon Wade • Janet Wadler • Margie Joy Walden • Mark Wallace • Kathleen Walsh • Fay Wanetick • Carolyne J. Warren • Matthew Warshauer • Rebecca Watkins • Virginia Watson • Al Weiss • Phyllis Weiss • Doris Welsh • Stephen Welsh • Stuart and Gisela Wemple • Angela West • Timmy J. Whishehunt • Vera Whittow • Pam Whitmore • Charlene Whitney • Rosemary Whitten • Martina Wiedmayer • Hal Wiener • Sondra R. Wiener • Geri and Rick Wietz • Jude Wiggins • Michael Williams • Heather Williams • David and Beverly Williams • Michael Willmore • Timothy and Veronica Wilson • Richard Wilson • Janet Wilson • Boyd Winck • Page Wingfield • Edward Winn • Megan Wintersteen • William Winneski • E.M. and J.L. Wittenberg • Ennio Wolsink • Darrick Wong • Susan Woodward • Jacob Wright • Debra Wysoval • Kiku Yamada • Leonard Yool • Debra Young • Phil Youngworth • Justine Yu • Donald Zakowski • Christine M. Zakutny • Betsy Zalaznick • Tim Zielinski • William and Rosemary Zumbiel •

ROBERT JAY WEINBERG MEMORIAL

Donations Have Been Made By:

Rochelle Ostrow-Weinberg

Wynnewood, PA
MEMORIAL DONATIONS HAVE BEEN RECEIVED IN THE NAME OF:

Harvey Adler • Jim Aerts • Craig L. Albers • Richard B Ammons • Richard Applebaum • Jean Avola • Katy Jo Ball • Joseph Babka • Lois Barnett • Fred Beile • David M. Bernstein • Frank Bigos • Mia Blumenstock • Robert W. Bolich • Herbert B. Bowes • Thomas “Tom” Bruch • Teri Burgess • David Hammond Burke • Frederick W. Burns, Jr. • Clem Cahall • John S. Calabrese, Jr. • Valarie Callan • Lillian “Cookie” Campo • Nancy Cappello • John Catanzaro • John “Buddy” Centurino • Romy Chow • Patricia Angela Chiccone Connor • Barney Cook • Jerry Dale Cowan • Clyde W Crooks Jr. • Wanda Curtis • Gale Cuvar • Marion K. Dale • Joseph Davis • Allan de Montagnac • Alessandro Degl’Innocenti • John L. DeNet • Margaret Ann DeTesta • Barbara L. Demers • Dominic Devito • Marlin Eugene “Mike” Dietrich • Billy Joe Dilbeck • David L. Duggan, Sr. • Joyce Collier Earl • Harley T. Emmons, Jr. • Arthur H. “Bushy” Epstein • William Felder • Kenneth B. Ferrin • Suzanne Fleischman • Allen Foster • Nancy C. Fox • Joan Clarke Frejd • Herbert G. Frey • Catherine “Cathy” Fry • Andrew Paul Glasgow • Tereze Gluck • Laine Gold • Marian Grady McNeely • Fredric S. Griste • O P Gupta • Mary Lou Hammond • Michaela Hancock • James Joseph Hannagan • James D. Harding • Martin Heiss • Linda Heller • Andrew E Helmich, Sr. • Marilyn Herald • George Michael Herrmann • Marjorie Hewett • Rita Hisrich • Jacqui C. Hoang • Kenneth Hoffman • Barbara Isaacs • Patricia Jackson • Elizabeth Norris Johnson • Mary Catherine Johnson • Gail E. Jolin • Juanita P. Jones • Rickard J. Joseph • Don Kane • Kathryn Karam • Christopher Masaaki Kimber • Arthur “Art” F. Kirk • Joe Kirsh • Cindy Klein • Roger Kloepping • Roy T. Kobashigawa • Ruth Koskinen • Anthony “Tony” Eugene Krauss • Joseph John Krivak • Thomas Krummen • Jerome “Jerry” Kuskowski • Eugene “Yudie” “Pops” Lang • Claudette Latsko • Jerry Lauder • Edward LeCount • Jacqueline List • Theresa A. Magown • Raymond W. Malles • Harlon Malone • Gerald Mandell • Nancy E. Manheim • Elefterios Mantas • Kenneth Wayne McAnally • Robert W. McCourt • Leah McDermid • Joseph A. McDermott • Anne Claire Gregory • Lorene McQuillar • Elsa Mederos • Ralph Mehan • Franklin T. Meisenberg • Wayne R. Meling • Robert Miller • Lee Miller • Allan Minor • Donald L. Mincemoyer • Michael Mitek • Howard Mobley • Taylor Moen • Manuel F. Moreira • Lillian Morris • Richard Morvay • David Mucci • Harriett Murphy • Judith “Judy” Klein Murray • Betty Joyce Narhi • Rosina A. Navagh • Corie Neri • Donna Ness • Virginia Newstorm • Robert K. O’Brien • Isabel O’Connell • Gary O’Connor • Arlene O’Donnell • Richard O’Hara • Terrence Ohst • Gloria Ostrowski • Graham Duncan Padgett Jr. • Dominic Pappaterra • Pappaterra • George H. Paul • Larry W. Pauley • Don A. Pfeiffer • Kieran Pillion • Daniel Paul Premuda • Douglas J. Purcell • Joseph Querol • Myron J. Radke • Lakshminarayan Ramawamy • David Chester Rankin • Theodore Ratkus • Dr. David P. Reed • Bonnie Reed • Frank Rehor • Linda C. Reilly • Marcia E. Resnik • Jon Arthur Reuscher • Stephen David Ricks • George Robokos • Elmer George “Rip” Rohner • Robert W. Ruark • Capt. Jim Ryan • James Michael Ryan • Ann Elizabeth Schlueter • Jack “Ty” Schuler, Jr. • Stephen M. Seidner • Kathleen M. Seiffert • Patricia Anne Seymour • Donald M. Shachat • Thomas H. Shuey • Roy Shumard • David Clay Sidebottom • Dale Simmons • Joy Slohower • Donald R. Smith • Edna Mae Smith • Leon A. Soltysoj, Jr. • Veronica A. “Ronnie” Sorrentino • Michael Sortino • Matthias Spanheimer • Maurice Howard Stallings • Marvin Steinke • Ray Stemler • Virginia R. Stephenson • Robert “Larry” Sterling • Raymond P. Stohner • Patricia Davey Struck • David Sundstrom • Evelyn Sylvester • Otto Ryan Szanto • H. Franklin Taylor, III • Philip N. Thomas • Milan P. Tomaska • HelgaPeskovíc • Jeannette Toth • Jack Turner • Robert “Archie” F. Tysarczyk • Carol Usher • Paul Valenzano • Rita B. Voit • Jim L. Warren • Charles Watkins • Stephen Whitney • Marc L. Wiener • Dolores Marie Wiley • Gary Wilson • Neal Wingfield • Richard Wold, MD • Arthur Wolfe • Thomas R. Wright • Edith Zachman • Lawrence M. Zuber

MEMORIAL FUNDS

MEMORIAL DONATIONS HAVE BEEN RECEIVED IN THE NAME OF:

The MDS Foundation’s Work Helps Keep Memories Alive

Honor or memorialize your loved one at: www.mds.foundation.org/donate or contact us at 800-MDS-0839 (within US), 609-298-1035 (Outside US).
Living Endowment Donations Have Been Made in Honor of:

Rob Allred
Submitted by: Matthew and Alison French

Kevin Z. Barefoot
Submitted by: Kevin D. Barefoot

Connie Bolduc
Submitted by: Derek and Kristi VerHeecke

Wyn Aubrey-Child
Submitted by: Donald Child

Ron and Janice Cook
Submitted by: Lauren Cook

Christine Cosenza
Submitted by: Drew Cucuzza

Edward DeCarbo
Submitted by: Carolyn Owerka and Alyasha Owerka-Moore

Estrella deVeyra
Submitted by: Robert deVeyra

Kathryn Ginn
Submitted by: Juddie Donaldson

David Karlin
Submitted by: Beverly Taylor, Gennady and Masha Farber, Pat and Tony Philipp
Mr. and Mrs. Stephen Wagstaffe

Drs. David and Joan Karlin
Submitted by: Kenneth Schwartz

Mary Pat Kollitz
Submitted by: Kelsey Zegar

Julia McGuire
Submitted by: Marguerite S. McKenna

Mahaveer Prabhakar
Submitted by: Rajeev Prabhakar

Sydney Rosenberg
Submitted by: Melissa Jones

Linda Smith
Submitted by: Renae Smith-Ray

Peter Suttner
Submitted by: Zach and Jen Suttner

Kathy Tchida
Submitted by: Daniel Huset

Marielle Thorsen
Submitted by: Marielle Thorsen

Barbara Unwin
Submitted by: Wayne and Lorraine Zerfas

Jill Whitney
Submitted by: Char Cervenka

Caitlin Wohlmacher
Submitted by: Ashley Pascoe

IN YOUR OWN WORDS

“I have just recently discovered your website, and I am VERY IMPRESSED with the resources you have available. I will be sharing with our patients and staff here at MGH.” – Maxine C.

“Read the online version of your Building Blocks of Hope and was very impressed. A LOT OF INFORMATION IN A SINGLE SOURCE. I believe the hard copy would be a valuable information source that will be of great use for me as well as other members of my family. I also think the handbook will be a very useful tool during treatment.” – Andrew M.

“Thank you so much for getting back to me so quickly and for all of the critical resources you offer through the foundation. You guys are the SOLE OASIS OF HOPE in an overwhelming sea of negative online search results and we are very grateful.” – Katherine M.

“The 14th International Symposium on MDS Patient Summary, May 2017 in Valencia, Spain, is ONE OF THE BEST I have ever read on MDS to date!” – Patrick C.

“Thank you for the Building Blocks of Hope! This is the BEST RESOURCE I HAVE FOUND on the internet!” – Janet P.

“Thank you for the treasure trove of information that just showed up in my mailbox. I will be devouring it page by page, with highlighter in hand. I will also be signing up for the community membership to help support your good efforts to educate people like me who need more information on this diagnosis. KNOWLEDGE IS POWER!” – Elizabeth S.

“I cannot even begin to tell you how much I APPRECIATE THE RESOURCES that you provided. This is a very useful source of information to help get my mom on the right track. We are just beginning our journey and understanding MDS and I want to do everything I can to help her. Thank you so much for all that you do! With gratitude…” – Molly M.

“This is a belated Thank You for the telephone conversation we had a few weeks ago and the trove of printed information that you sent me. In particular, I found much valuable detail in the Building Blocks of Hope. THE MDS FOUNDATION IS A GREAT AND VALUABLE RESOURCE and I have contributed to the Foundation and will continue to do so.” – Lewis G.

“Your MOBILE APP has been EXTREMELY HELPFUL TO ME and makes it so much easier than having to cart around all that paper.” – Nancy R.

“I have registered as a member of your foundation because I have VALUED YOUR WORK very positively. Thank you very much for helping people from all over the world to know more about this disease, congratulations.” – Roman S.G.

“WE ARE GRATEFUL HOW THE MDS FOUNDATION GIVES SUPPORT to all the patients and families like us. May God bless all of you and continue the great work.” – Angelica R.

“Last week we talked and you told me all about the MDS Foundation. Then you sent some WONDERFUL PUBLICATIONS that gave me a lot of insight about MDS. Thank you very much for your help. Today I mailed my MDS Foundation membership application.” – Bob B.
At Celgene Patient Support®, we care about making sure you get the help you need to start your prescribed Celgene medicine.

Our Specialists are ready to help you and your family with:

- Understanding your insurance plan
- Learning about financial assistance
- Obtaining information about organizations that may assist you with travel costs to and from your doctor’s office

Enrollment in Celgene Patient Support® is simple—choose the option that is best for you.

Enroll online at www.celgenepatientsupport.com

Call us at 1-800-931-8691, Monday – Thursday, 8 AM – 7 PM ET, and Friday, 8 AM – 6 PM ET (translation services available)

E-mail us at patientsupport@celgene.com
The Pivotal MDS Trial **INSPIRE**
is Now Recruiting Patients

**International Study of Phase III Intravenous Rigosertib**

**STUDY DESCRIPTION**
A Phase 3, international, randomized, controlled study of Rigosertib + best supportive care versus physician’s choice of treatment + best supportive care in patients with myelodysplastic syndrome (MDS) after failure of a hypomethylating agent (HMA).

**Eligibility:**
- MDS subtypes RAEB-1, RAEB-2, or RAEB-t
- Progression or failure to respond to HMA
- HMA treatment duration ≤ 9 cycles in ≤ 12 months
- ≤ 82 years of age

**Randomization:**
- 2:1
- Rigosertib + best supportive care N = 240
- Physician’s Choice of Treatment + best supportive care N = 120

**Primary Endpoint:**
- Overall Survival in the intention-to-treat population and in patients with very high risk per the Revised International Prognostic Scoring System (Greenberg et al, Blood 2012).

**INTERNATIONAL TRIAL**
More than 170 trial sites

**For additional information on this study, please call the INSPIRE help line at 1-267-759-3676 or visit www.clinicaltrials.gov, identifier: NCT02662443.**
Rigosertib is an investigational agent and is not approved by the FDA or other regulatory agencies worldwide as a treatment for any indication.
**NOW ENROLLING**

**PANTHER TRIAL**

**PEVONEDISTAT-3001 (NCT 03268954):** Designed to evaluate the safety and efficacy of pevonedistat plus azacitidine versus single-agent azacitidine as a first-line treatment for patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML)

- **Randomized 1:1**
- **Global phase 3 clinical study** (N=450)

**Primary endpoint:** Event-free survival (EFS)

**Key secondary endpoint:** Overall survival (OS)

Not a complete list of endpoints.

**Enrolling countries**
Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Greece, Israel, Italy, Japan, Mexico, Poland, Russian Federation, South Korea, Spain, Turkey, UK, USA

**For more information, including all inclusion and exclusion criteria**
1-844-ONC-TKDA (1-844-662-8532) (US callers)
+1-510-740-1273 (ex-US callers)
www.clinicaltrials.gov or www.takedaoncology.com

**For information on enrolling a patient, please contact GlobalOncologyMedInfo@takeda.com.**

Pevonedistat is an investigational drug. Efficacy and safety have not been established.
Phase 3 Clinical Trials NOW ENROLLING

Guadecitabine (SGI-110) in MDS or CMML

408-Patient Multicenter, Randomized, Open-Label Study in Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) After Failure of Prior Azacitidine, Decitabine, or both

For more information: www.clinicaltrials.gov
Identifier: NCT02907359 or
Email: ASTRAL-3@astx.com

Oral ASTX727 LD in Lower Risk MDS

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

For more information: www.clinicaltrials.gov
Identifier: NCT03502668 or
Email: ASTX727-03LD@astx.com

For a full list of eligibility requirements go to clinicaltrials.gov